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ABSTRACT 
 
Background:  While Selection of reverse transcriptase (RT) mutation has been 
reported frequently, protease (PR) mutations on antiretroviral therapy (ART) including 
boosted Protease inhibitor (PI) have not been reported as much in Zambia. Affordable 
in-house genotyping assays can been used to expand the number of patients receiving 
drug resistance geno-typing, which can aid in determining prevalence of RT/PI 
emerging mutations. 
Methods:  A previously published drug resistance genotyping assay was modified and 
used to genotype RT and PR genes. 19 patients virologically failing first-line regimen 
and 24 failing second-line regimen were studied to determine resistance patterns. 
Virological failure was defined as failing to maintain <1000 copies/mL during ART.  
Only major and minor RT and PR mutations (IAS-USA 2010) were considered for 
analysis. The in-house assay was validated by comparing sequence data of 7 previously 
ViroSeq tested samples and 5 randomly selected samples to determine reproducibility.    
Results: The in-house assay efficiently amplified all 12 validation samples with the 
lowest sample scoring 99.4% sequence homology. The most common RT mutation was 
M184V (79% n=19) and (71% n=24) first and second-line respectively. No significant 
differences were reported in all the other RT mutations between first-line and second-
line regimens.  Drug resistant PI mutations (I54V, M46I and V82A all present 20.8%) 
were only found in the second-line regimen and were insignificant, p= 0.0562. 
 
Conclusion: The in-house assays can be used as alternatives for commercial kits to 
genotype HIV-1C in Zambia without compromising test quality. The insignificant PI 
drug resistant mutations which were found, despite virological failure in patients, could 
indicate a possibility of other mutations within the HIV-1 genome that could reduce PI 
susceptibility. 
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1.0 CHAPTER 1: INTRODUCTION 
1.1 INTRODUCTION 
Human Immunodeficiency Type-1 (HIV-1) and Acquired Immunodeficiency 
Syndrome (AIDS) are the major causes of mortality and morbidity in Sub-Saharan 
Africa [1]. According to the World Health Organization (WHO), by the end of 
2010, about 34 million people were living with HIV and a total of 2.7 million were 
infected that year.  A total of 1.8 million people died of AIDS during the course of 
that same year. Regional statistics indicated that about 22.5 million (about 67%) 
HIV positive individuals were from Sub-Sahara Africa and 1.9 million (about 
69%) new infections were recorded from the same region. About 1.3 million (72%) 
deaths were recorded in 2009 in sub-Saharan Africa.  Over 7,000 people are 
estimated to be infected by HIV each day with over 97% of these infections 
occurring in low and middle income countries [2]. 
For some time now, effective Highly Active Antiretroviral Therapy (HAART) has 
been available in developed and some third world countries which has prolonged 
the quality of life of those infected with type 1 HIV. Measurements of both 
absolute CD4 (cluster of differentiation) count and plasma HIV-1 viral load (VL) 
have been used as important parameters in patient management for both initiation 
of treatment and during Antiretroviral Therapy (ART) [3].  Numerous evidence has 
shown that a combination therapy with HAART, that inhibits the viral enzymes 
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such as protease and reverse transcriptase, significantly reduces HIV-1 replication. 
This has resulted in the reduction of mortality and morbidity associated with HIV-
1/AIDS in the past decade [4-6]. 
Figure 11a below shows the world statistics for the selected region for the total 
populations on ART as compiled by the World Health Organization (WHO). 
World regions are identified by the color coded bar chart from the end of 2002 to 
the end for 2010 cumulatively. The figure was drawn based on WHO global 
HIV/AIDS progress report 2011. 
 
Figure 1.1a. shows an upward trend in the access to ART between 2002 and 2010 according  WHO 
global HIV/AIDS progress report 2011 [7]. 
 
As can be seen in figure 1.1a, the WHO reported a rise of antiretroviral (ART) 
coverage from 7% in 2003 to 47% by end of 2010 with eastern and southern Africa 
having had the highest coverage (48%). [1] 
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Zambia has been reported to be amongst the countries in sub-Sahara with the 
highest HIV prevalence.  By the end of 2009, the WHO reported that 
approximately 980,000 (about 2.8% of the global epidemic) people were living 
with HIV/AIDS in Zambia alone. The adult (aged 15-49) HIV prevalence in the 
same year was 13.5% and approximately 45,000 HIV related deaths were reported.  
The number of people receiving antiretroviral therapy in Zambia by the end of 
2009 was estimated to be around 284,000, with about 70-79% needing therapy. 
Figure 1.1b below summarizes the strides accomplished in the last decade in 
preventing HIV related deaths using ART in Zambia [7] 
 
 
Figure 1.1b. Data of people living with HIV (blue) and deaths (red) due to AIDS between 2002 and 
2009 in Zambia [7].  
While HAART is a positive achievement in one sense, a long-term obstacle to it is the 
emergence of resistant HIV-1 variants which are less susceptible to ART drugs [8, 9]. 
Some of the attributed causes of this include mono-therapy, inadequate suppression of 
the virus replication e.g. due to lack of adherence to treatment, late initiation of 
HAART, and high viral replication rates coupled with high mutation errors [10-12].  
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Drug resistance testing has therefore become increasingly important in the 
identification of viral mutants that confer with drug resistance in patient clinical 
management.  A number of guidelines that recommend these tests and interpretation of 
results have since been published [13-15]. 
In the next section I will give an overview of the HIV-1 genetic classification, 
replication cycle, host immune response and genetic diversity as a basis for 
understanding the HIV mechanism of resistance to currently used antiretroviral therapy 
during drug resistance.   
1.2 THE HUMAN IMMUNOVIRUS TYPE I (HIV-1) 
1.2.1 Introduction  
Human Immunodeficiency Virus (HIV-1) is the main etiological agent of Acquired 
Immunodeficiency Syndrome AIDS. The virus was first isolated in the early 1980s 
from the blood of AIDS patients [16, 17]. HIV is transmitted from one infected 
individual to another through exposure of bodily fluids such as semen, blood, breast 
milk, amniotic fluids and vaginal fluids [17].  Common modes of transmission include 
unprotected anal or vaginal sex with an infected person, blood transfusions, 
transmission from mother to child during pregnancy, childbirth or breastfeeding, and 
through contaminated hypodermic needles [18-21]. HIV infection is characterized by 
long periods of clinical latency as well as weakened acquired immune responses and 
persistent viremia without medical intervention, patients eventually develop AIDS [22]. 
1.2.2 Classification  
HIV is the prototype of the lentivirus genus, subfamily of retrovirus. An HIV-1 particle 
possesses identical single-stranded ribonucleic acid (RNA) genome, approximately 
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9.2kb long that are packaged in a cone-shaped capsid core particle [23]. Retroviruses 
contain internal structures which are important for viral replication and invasion of the 
host cell’s defense. Some of the other viruses of the lentivirinae include the simian 
immunodeficiency virus (SIV), which causes an AIDS like disease in Asian monkeys, 
and equine infectious anemia virus (EIAV)  that causes anemia in horses [22]. 
There are currently two major groups that HIV isolates have been classified as, namely, 
HIV type 1 (HIV-1) and HIV-type-2 (HIV-2). Classification depends on the genetic 
variation [24]. HIV-1 variants are either grouped as major (M), outlier (O), or new or 
non-M (N).  Group M is the major causative agent for AIDS and accounts for more 
than 90% of infections worldwide  [25].  Group M has further been divided into 
subtypes A, B, C, D, F, G, H, and K [24]. Individuals with dual or multiple infections 
usually have different strain recombination forming a sub-subtype designated CRFs 
(circulation recombinant forms) and there are more than 40 CRFs worldwide [26]. 
HIV-1 subtyping has often  been determined using the V3 (variable-3) serotyping, 
envheterodulex mobility assay [27] or PR and RT nucleotide sequencing [28]. 
1.2.3 Genomic Structure 
The mature HIV virion is generally characterized by having an outer lipid bilayer 
envelope of the host cell it was derived from. Studded within the envelope are several 
proteins from the host cell including major histocompatibility class 1 and 2 (MHC-
I/MHC-II) antigen, actin, and ubiquitin. These proteins have been isolated from 
purified samples of both HIV-1 and HIV-2 as well as in SIV [29]. High resolution 
microscopy has reviewed the HIV-1 virion to be icosahedral in structure with 72 
external spikes formed from glycoprotein 120 (gp120) anchored to the surface through 
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a trans-membrane protein, glycoprotein 41 (gp41) [30]. These envelope proteins are 
encoded by the env gene. Most retroviruses that replicate possess only three genes, gag, 
pol and env but the HIV-1 also contains six additional regulatory genes namely vif, vpu, 
vpr, tat, rev and nef  which have been shown to be important in the replication process. 
HIV-1 mutants that lack functional regulatory genes are less adaptive as compared with 
the wild type [31-34]. The gag polyprotein sequence encodes HIV core structural 
proteins which include matrix (MA), capsid (CA) and nucleocapsid (NC) proteins [35]. 
The pol gene encodes reverse transcriptase (RT), integrase, and protease (PR) enzymes. 
HIV genomic RNA can be primary seen as a coding of the above nine reading frames 
that encode for 15 proteins [35] , see figure 1.2 
 
 
Figure 1.2 is an illustration of the HIV-1 genome showing the nine known genes and their summarized 
functions. Also depicted are the 5’and 3’ long terminal repeats (LTRs) and the regulatory sequences 
recognized by various host transcription factors.  Figure drawn based on online published structures [36, 
37]. 
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1.3 HIV-1 REPLICATION CYCLE 
In vivo, the HIV-1 life cycle can be looked at from the time the virus enters the host 
cell to the time it produces new viral particles. The process has been divided into 
several stages: entry, reverse transcription, integration, and budding. 
1.3.1 HIV-1 Entry 
The viral envelope protein glycoprotein surface unit, SU, gp120 initiates the host cell 
(lymphocytes and monocytes) infection for HIV-1 through cognate recognition of the 
amino-terminal immunoglobulin domain of CD4 [38, 39].  HIV-1 has a strikingly high 
affinity for the cellular receptor (CD4) which is considered the sole high-affinity 
receptor for this retrovirus. The interaction of the gp120 and CD4+ receptor is 
however, only adequate for viral-cellular primary binding and not fusion. Viral fusion 
is triggered by one of the several chemokine receptors which include CXCR4 and 
CCR5 [40-42].   The CD4-gp120 interaction induces a conformational change that 
unfurls the hydrophobic N terminus of the second envelope protein, gp41, that drives 
the fusion of the viral particle with the cellular membrane via interaction of any of the 
above mentioned chemokines [40, 43].  On the basis of tropism, HIV can be 
categorized as either macrophage-tropic (M-tropic) or T-cell-tropic (T-tropic). Viruses 
(R5 viruses) that are M-tropic use CCR5 as co-receptors while X5 viruses (T-tropic) 
use CXCR4 as co-receptors. R5 viruses poorly infect CD4+ T-cell lines as compared to 
macrophages and primary T cells [44] while X4 viruses have been reported to 
effectively infect CD4+ T-cells as they highly express the CXCR4 co-receptor [45]. 
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The CCR5 receptor mutation can protect the cells from HIV infection but overall cell 
benefits do not seem significant as other chemokine receptors are thought to replace 
their functions. R5 stains predominate during the early course of infection before both 
strains can be recovered [42]. Figure 1.3 below shows a summary of the HIV-1 life 
cycle in a CD4/CXCR4 or CCR5 positive T cell (see arrow 2). 
 
Figure 1.3 Small arrowheads (1-7), viral entry to integration. Curved arrows, early replication 8-10; 
double headed arrows (11-15), late replication. Graph adapted from Scherer et al [46]. Red arrows depict 
varied positions that drug inhibiting viral replication are targeted on.   
1.3.2 Reverse Transcription 
Once the HIV viral particle enters the cell, the viral capsid releases the viral reverse 
transcription complex. Reverse Transcriptase (RT), an enzyme that comes pre-packed 
in the mature HIV particle, catalyzes the reverse transcription of the viral single 
stranded RNA genome to form double stranded complimentary deoxyribonucleic acid, 
cDNA. Host cellular lysine transfer-RNA (tRNA) is used as a primer in this process 
Stellenbosch University  http://scholar.sun.ac.za
9 
 
[47].  Vif, a 192 residue protein, has been shown to play an important role in viral 
replication as Vif mutant viruses have shown significantly reduced levels of viral 
complementary DNA (cDNA) synthesis and produce highly unstable replication 
intermediates [48, 49]. The translation process of the viral RNA genome is error prone 
[50-52] and increases four-folds in the absence of HIV-1 regulatory gene vpr [53, 54]. 
A number of Nucleotide Reverse Transcriptase (NRTIs) and Non-Nucleotide Reverse 
Transcriptase (NNRTIs), as was previously stated, have been developed to inhibit 
reverse transcriptase. 
1.3.3 Integration 
The end product after reverse transcription of the HIV-1 genome is cDNA pre-
integration complex which is shuttled into the nucleus, a process vpr and vif are 
reported to participate [55, 56]. Integration cDNA into the host genome occurs 
randomly in reactions catalyzed by the viral integrase enzyme. The first integrase 
inhibitors were reported about 20 years ago [57-59] but currently only one drug, 
Raltegravir, is FDA approved [60]. 
1.3.4 Maturation and HIV-1 release 
Cellular transcription factors activate a low level production of regulatory short 
multiply spliced genes, Rev, Tat and Nef, that can  then amplify the viral transcription 
rate up to a 1000-folds [61, 62]. Rev, another gene which was mention earlier, has been 
reported to facilitate the exportation of unspliced viral mRNA into the cytoplasm [63-
68]. Tat, Nef and Rev have been targeted in HIV-1 at the level of pre-mRNA splicing 
to significantly retard viral replication. This approach in combination with other 
antiviral strategies may be a useful tool in the fight against HIV/AIDS [69]. 
Stellenbosch University  http://scholar.sun.ac.za
10 
 
Pre-protein, pr55gag translated from singly spliced gag mRNA and Gag-pol are 
synthesized as precursor non-infectious polyproteins and Gag cleaved into the mature  
proteins p17 matrix (MA),p24 capsid (CA), p7 nucleocapsid (NC), and p6 during viral 
maturation by the viral protease enzyme [70-72]. An intermediate-length mRNA pre-
protein encodes glycoprotein gp160 that is cleaved by proteases to originate Vpr, Vpu, 
gp41 and gp120 [73].   Gag-pol pre-protein encodes viral enzymes protease (PR), 
integrase and RT. Inhibition of PR markedly suppresses the viral replication [74]. 
1.4 IMMUNE RESPONSE AND DISEASE PROGRESSION OF HIV-1 
INFECTION 
Following infection, HIV-1 has a tropism towards CD4+ cells as has been mentioned 
before, and is disseminated throughout the lymphoid system and rapidly replicated 
within the infected cells. Within two weeks of infection, the viremia reaches peak 
levels, up to 107 copies/ml, before dropping to a set-point in the subsequent months. 
The set-point is predictive of how rapidly an individual will progress to developing 
AIDS [75]. The set-point varies by individual. 
The clinical course of HIV infection can be divided into three stages: (a) primary 
infection (Acute HIV infection), (b) clinical latency (Chronic HIV infection), and (c) 
development of AIDS.  
1.4.1 Acute HIV-1 Infection (Primary infection) 
Acute infection is the period between infections of HIV-1 to the time the HIV-1 
specific antibodies are detected 3 to 4 weeks later [76]. Following sexual transmission, 
the most common form of transmission, HIV-1 has been suggested to replicate locally 
in the genital tract or rectal mucosa cells that express CD4 and CCR5 receptors before 
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it can be detected in the plasma [77, 78]. This period is also referred to as the eclipse 
phase, and offers a small window of opportunity for the immune system to eliminate 
the virus before it archives into host genome [79]. Infection symptoms include: 
 common cold or flu, fever, fatigue, headache, sore throat swollen lymph nodes, and, 
often, rash. The severity of symptoms differ for patients while some don’t experience 
any [80]. 
Single genome amplification and sequencing  has shown that up to 80% of mucosal 
infection occurs from a single virus, the funder virus, which has been shown to infect 
CD4+ T cells more efficiently than monocytes or macrophages [81]. The innate 
immune activation at this stage can contribute negatively by recruiting a number of 
immune cells such as lymphocytes, macrophages, and granulocytes. The lymphocytes 
become the target for more infections later, while the other two cell types engulf the 
virus and together with the infected lymphocytes disseminate the virus at other sites 
such as the lymph nodes [82]. 
During acute infection, most of the HIV-1 fails to produce productive viral particles 
due to the high error rate of the viral replication process as well as the intervention by 
the antiviral activities of the host’s catalytic Apolipoprotein B mRNA-editing 
polypeptide-like cytidine deaminases-3G APOBEC3G, which increase the rate of 
defective viruses being produced. This allows for deaminases resistant HIV-1 mutation 
variants to be selected [83].  
At the end of the eclipse phase, the virus is drained into the lymph nodes mainly by the 
dendritic cells where they meet more activated CD4+CCR5+ T cells which act as 
targets for further infection. Eventually the viruses are spread to other parts of the body 
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including lymphoid tissues such as the gut associated lymphoid tissue (GALT). These 
tissues house a great number of activated CD4+CCR5+ memory T cells which a study 
has shown that up to 20% can get infected during the acute phase and 60% are depleted 
through Fas-mediated apoptosis of both infected and uninfected cells within three 
weeks. Mucosal depletion of CD4+CCR5+ memory T cells are the most affected 
during this phase [84]. During this phase of infection the patient experiences an 
exponential burst of viremia to a peak of up to 107 copies/ml and a drop in CD4+ T 
cells count [84]. 
After reaching peak viral load, the host immune system eventually decreases the viral 
load over a period of 12-20 weeks to a stable level known as set point. This period 
correlates with the maintenance of robust T-helper CD4+ T-cell and (cytotoxic T-
lymphocytes (CTL) responses. Recent studies have shown that primary HIV-1 specific 
T cell response concurrent with failing viral load during the acute phase rapidly selects 
escape mutations. CD8+ T cells have been shown to play a significant role in the 
control of infection during this phase [85-89]. This is another way that the immune 
response exerts selective pressure on HIV that mutates and contributes to the pool of 
viral variants being generated by the erroneous HIV-1 reverse transcriptase [90]. 
1.4.2 Chronic HIV-1 Infection (Clinical latency phase) 
The chronic phase of infection is a period of clinical latency during which circulating 
CD4+ T cells return to near normal levels and the patient is asymptomatic for an 
extended period of time. A number of studies have reported the period of a median time 
of disease progression to be about eight to ten years for typical progressors [91, 92]. 
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During this period, viral replication persists and is associated with a progressive 
depletion of CD4+ T cells and deregulation of HIV specific CTL function [93, 94]. 
A striking feature of the chronic stage is the activation of innate cells: B cells and T 
cells. This is evident in the increased activation of biomarkers such as CD38, 
considered the most reliable surrogate marker for immune activation, disease 
progression to AIDS, and death, Ki67, and HLA-DR [95, 96]. Chronic immune 
activation and AIDS progression are rarely observed in naturally SIV infected sooty 
mangabeys- an indication of the role activation plays in disease progression. This 
occurs despite CD4+ cells depletion [95, 97].  Associated with immune activation 
during the chronic stage are B and T cell early and extensive apoptosis.  This in turn 
results in an increase in tumor necrotic factor (TNF) – related apoptosis inducers such 
as immune suppressors and a killing of bystander cells. Such inducers include tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas ligand, TNF 
receptor type 2 (TNFR-2), and plasma micro-particles [98]. 
Although the exact mechanism of immune activation during early HIV-1 infection is 
not clearly understood, implications include; (a) damage of the gut due to CD4+ 
memory T cell depletion which leads to bacterial product translocation (for example 
Lipopolysaccharide, LPS) in to circulation and (b);   viral components such as gp120, 
nef and viral nucleic acids which during replication activates pro-inflammatory 
cytokines and type I interferon both IFN-alpha and -beta [99]. 
The ultimate result of immune activation is a depletion of CD4+ T cells, a reduced half 
life of both CD4+ and CD8+ cells,  exhaustion of clonal T- cells, dysregulation of T – 
cell trafficking, and drainage of memory T cell reservoirs [100].  
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CD4+ T cell depletion corresponds with elevation of viremia and thus serves as marker 
of patient prognosis (Fig 1.4). 
 
Figure 1.4 Typical course of HIV infection that depicts the relationship between the levels of HIV (viral 
load) and CD4+ T cell counts over the average course of untreated HIV infection shown in solid red 
(CD4+ T cell count) and black lines ( plasma viral load). Shaded area indicates treatment period. The 
broken line within the shaded blue is indicating the typical trend upon HAART. Figure was drawn using 
Graphpad Prism5. 
 
The introduction of HIV antiretroviral drugs over the past two decades has changed the 
perception of HIV infection being a death sentence. Most of these drugs however have 
been shown to quickly reduce in efficacy and patients develop drug resistance when 
used in suboptimal concentrations, which is common during mono therapy [101]. Drug 
resistance is a subtle change that occurs in the balance between enzymatic recognition 
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of drug inhibitors and the normal physiological substrates. Following drug pressure on 
the HIV-1 drug treatment, viruses with mutations are able to change the enzyme’s 
conformation to reduce drugs from binding on the active sites that preferably get 
selected  [102]. 
When several of these drugs are used in combination, the approach of treatment is 
known as Highly Active Antiretroviral Therapy (HAART). HAART with adherence of 
above 95% has been demonstrated to effectively suppress HIV-1 RNA plasma viral 
load to below detectable limits for a long period of time. It can enable immune 
reconstitution as well as avert disease progression [103], see Figure 1.4. Commonly 
used highly active antiretroviral therapy (HAART) typically comprises a three drug 
combination: two Nucleoside reverse transcriptase inhibitors (NRTIs) and one non-
nucleotide reverse transcriptase inhibitor (NNRTI) or Protease inhibitor (PI)[104]. Each 
of the drug categories is meant to inhibit a particular process of the viral replication and 
if properly used with drug resistance testing, can improve virologic outcome [104].   
Since drug resistance mutation arise most from the selective pressure mounted on the 
enzymes targeted by therapy, many of which compromise the function as was reviewed 
above, the mechanisms of each of these three drugs categories and Protease and 
Reverse Transcriptase (RT) enzymes will be reviewed below in more detail. 
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1.5 Genetic diversity of HIV-1 
There is an enormous genetic diversity of HIV-1 both within and between infected 
people [105] due to the rapid replication rate of the virus, the size of the viral 
population within individuals, and extensive viral recombination [25, 106]. This 
diversity allows HIV-1 to survive and persist despite drug therapy during ART [107].  
The core root of drug resistance arises from mutations occurring during viral 
ribonucleic acid (RNA) reverse transcription. This seems to be the cause for the 
extreme adaptability for the retrovirus. The reverse transcriptase (RT) do not have 3’-5’ 
exonuclease proofreading activities making their error rates several fold higher when 
compared with the cellular DNA polymerase [52, 108]. Crystal structures for the 
reverse transcriptase and RNA polymerases have confirmed the lack of the domain 
responsible for 3’ to 5’ exonucleolytic proofreading activities. Such a domain is present 
in cellular enzymes, such as the DNA dependent DNA polymerase from Escherichia 
coli which is responsible for mismatch repair [108-110]. 
The exonuclease activities of DNA polymerase are essential for the removal of 
mismatched nucleotides during replication. DNA Polymerase has a proofreading 
mechanism and has been reported to enhance substitution accuracy in eukaryotic 
replication up to 10-7 to 10-8[111].  For example, the human genome has about six 
billion nucleotides and is replicated within a few hours with an error rate of less than 
one mutation per genome in one cell cycle. The proofreading activity of the polymerase 
is reported to play a significant role in this high fidelity [112]. 
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In addition to lacking a proofreading mechanism, the RT also has an intrinsic ability to 
jump between templates during DNA synthesis [113, 114]. The result is an extremely 
high rate for recombination between the cellular and the viral RNA, between co-
packaged genomes and between various regions of the viral genome [115]. 
Three main ways mutations can occur during HIV-1 retroviral replication include:  
(i) when the provirus DNA integrated with the infected host cell is being replicated 
by the DNA dependant DNA polymerase during cell replication [113-115] 
(ii) during viral transcription from the provirus by the DNA dependant RNA 
transcriptase [113-115] and 
(iii)during conversion of single stranded HIV-1 viral RNA into double stranded 
DNA by the reverse transcriptase [113-115]. 
Studies have estimated mis-insertion errors during replication and retro-transcription of 
the HIV genome (approximate 10 kb) to be in the range of 10-3 and 10-5 per nucleotide 
site in one replication cycle. This translates to each progeny RNA or DNA molecule 
including an average of 0.1-10 mutations [50-52]. In other words, a newly infected cell 
can thus be said to contain a provirus that differs from the previous infected cell by 
about one mutation. A potential thus exists for every possible point-mutation to be 
generated thousands of times a day given that about a billion cells are infected each day 
during a chronic infection [116].  
 As has already been alluded to above, such a high mutation rate is mainly attributed to 
the low efficiency of proofreading repair activities associated with RNA replicases and 
transcriptases [108].  
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The adaptations mentioned above summarize to form what has been referred to as a 
quasispecies complex. A theoretical quasispecies complex was originally defined by 
Eigen and colleagues as dynamic distributions of non-identical but related replicons 
that can result in a steady-state of organized distribution of error copies to the master 
sequence [117]. The mutant complexity increases as the fidelity of replication 
decreases, consequently increasing the viral fitness [117, 118].  However, this 
theoretical concept differs with replication occurring in the real and ever changing viral 
environment in that a steady state of equilibrium distribution in viral populations 
infecting host organism and cell culture is difficult to attain [118]. During HIV antiviral 
therapy, many studies have shown drug pressure to result in a selection favoring the 
genotypes, in association with mutation, that seem to have the highest replication rates 
[106, 117, 118].   Quasispecies complexes therefore allow a broad spectrum of mutants 
to be generated and constantly compete with one another. If the environment remains 
constant, a ‘steady-state’ is formed where each mutant is represented according to its 
fitness [106].  
Within the quasispecies exists mutants that would have evolved to enhance their 
physiological function to easily escape drug pressure. One such function is the 
mutations that enable the RT to have structural changes which results in a high affinity 
of  physiological dNTP as opposed to analogue drugs [119-121]. 
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1.6 STRUCTURAL FUNCTION OF HIV-REVERSE TRANSCRIPTION 
 
Reverse transcriptase is a hetro-dimer enzyme consisting of a 560 amino acid subunit 
(p66) and a 440 amino acid subunit (p51) both derived from the pol polyprotein [35]. 
The first reverse transcriptase  crystal structure (3.5A), in relation with function, was 
determined by Kohlstaedt et al. [122] and has set the basis of understanding how any 
change in this conformation might result in a functional modification of the enzyme. In 
this structure, the N terminal 440 amino acid of p66 forms the polymerase part of the 
enzyme while the C-terminal 120 amino acids form the Rnase sub-domain.  The Rnase 
and the polymerase are connected by sub-domain named connecting domain [122].  
The polymerase units themselves are comprised of three sub-domains whose 
conformation anatomically resembles the right hand leading to the naming, palm, 
fingers and thumb [122]. The finger, palm, and thumb form a cleft that resembles that 
of Klenow fragment E. coli DNA polymerase 1 and comprises the DNA polymerase 
catalytic sites which harbors a triad of aspartate asp110 (D110) Asp185 (D185) and 
Asp186 (D186) residues.  D185 and D186 are part of highly conserved tyrosine-
methionine-aspartate-aspartate (YMDD) motifs, common with Klenow fragment E. 
coli polymerase with which any mutations and any of the aspartate in those motifs 
severely reduces pol activity [123]. Together the palm, finger and thumb act in 
synchrony as a clamp that positions template primers relative to the polymerase site 
[124]. 
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The p51 domain of the HIV-1 RT lacks the entire 120 amino acid Rnase sub-domain. 
Despite its sequence also being identical with the N terminal 440 amino acid of the 
p66, the conformation is different and the p51 has no polymerase activity. The 
conformation in this structure is in such a way that it lacks the cleft (pocket): the D110, 
D185 and D186 thought to be important for catalysis are buried in the structure, and the 
fingers fold toward the palm and the thumb away from the fingers. This makes the 
p66/p51 heterodimer  have only pol activity within the p66 [122]. 
Studies of RT polymerase ternary complex with dNTP in the nucleotide pocket suggest 
that the binding of a correct nucleotide (substrate) forms a closed structure that allows 
residues of the fingers in the sub-domain to become part of a complete functional 
binding pocket essential for nucleic acid polymerization [125]. Mutations of a number 
of residues within the palm and fingers of the RT are thus not surprisingly associated 
with most of the drug resistance of nucleoside-analogs that occur during ART as they 
alter normal conformation that defines the catalytic site [125]. 
The role that specific amino acids have in the specific positions of the HIV-1 RT has 
been studied by many scientists across the globe both in vitro and in vivo. In vitro tests 
are done usually by passage experiment in which HIV-1 viruses are cultured in 
increasing drug concentration which selects the resistant strains. HIV-1 constructs that 
contain known mutations can be passaged in such a test enabling the researcher to 
correlate mutation occurrence with enzyme function.  HIV-1 mutations can also be 
characterized by studying viruses from patients failing therapy. This, as opposed to in 
vitro studies, offers a much broader information that can be used to correlate mutations 
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with patient drug history; correlate mutations with virologic response to new drug 
regimens or correlate HIV-1 mutations and drug susceptibility [126].  
Examples of an outcome from such studies include RT in complex with DNA double 
strand studies that have  reviewed that the amino acid residues such as Methionine 184 
(M184), glutamic acid 89 (E89), glutamine 151 (Q151), mapped in the palm play an 
essential role during replication. For example, the M184 residue is suggested important 
for the interaction with the primer 3’ hydroxyl terminus and the incoming dNTP. The 
E89 residue provides the template DNA with a grip while the Q151 makes contact with 
the nucleotide [127]. 
Others such as Lysine residues 65 (K65) and leucine 74 (L74), are found in the distal 
region of the dNTP binding pockets within the polymerase fingers but are significant in 
making contact with the phosphate of the incoming nucleotide as well as positioning 
the templating base respectively [125]. 
Evidence of other amino acid residues such as K219, T215, L210, K70, D67, and M41, 
found in the palm and finger domain, has shown mutations of such residues alter the 
conformational structure of the RT that result in reduced sensitivity to some drug e.g. 
AZT and 3TC [128, 129]. 
Figure 1.5 shows the structure of  RT. In A, the enzyme is shown in complex with 
DNA while in B; emphasis is on the two drug binding sites, NNIBP and dNTP in 
relationship with surrounding amino acid residues that are the frequent point for 
mutations. 
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Figure 1.5.The structure of the HIV-1 RT catalytic complex. (A) Some of the RT catalytic complex 
depicting the RNase H domain on the right and polymerase active site on the left. For the domains of p66 
all in color: fingers (blue), palm (red), thumb (green), connection (yellow), and RNase H (pink); p51 is 
shown in gray. The template DNA/primer complex is in white and orange threads; the NNRTI is in 
yellow and white spheres, figure adapted from Rhee, et al. (2003) [130];  and (B) Location of some 
specific NNRTI-resistance mutations (red) and NRTIs (green). NNIBP (Non-nucleoside inhibitor 
binding pocket.) and dNTP binding site docked with dNTP showing the location targeted by nucleoside 
analogues. Figure was drawn based on figure adopted from Domaoal, et al. (2004), [131].   
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1.6.1 Medical implications 
Considering the role that the RT enzyme has in the viral replication cycle, a number of 
drugs, Reverse Transcriptase Inhibitors (RTIs), have been developed that aim to 
suppress its function. These drugs fall into two categories: those that mimic 
deoxyribonucleotide (dNTP) but terminate the elongation of the growing chain during 
replication called Nucleotide Reverse Transcriptase inhibitors (NRTIs), and those that 
inhibit the RT enzyme function in other ways than mimicking physiological dNTPs 
called Non-Nucleotide/Nucleoside Reverse transcriptase Inhibitors (NNRTIs). 
1.6.2 Nucleoside or Nucleotide Reverse transcriptase inhibitors (NRTIs) 
All drugs that have been approved by the FDA that inhibit the reverse transcriptase fall 
in two categories mentioned above, NRTIs or NNRTIs. The general principle of the 
first category, NRTIs, is that they provide the HIV-1 reverse transcriptase with 
nucleoside or nucleotide analogues that mimic the cellular nucleosides needed in the 
early stages or replication during reverse transcription. During normal HIV-1 
replication, the infected host cells provide the virus with physiological nucleosides that 
are activated to nucleotides essential in the transcription of template viral RNA by the 
HIV-1 RNA dependent DNA polymerase. Nucleoside analogues are competitively 
incorporated in the growing HIV-1 DNA chain, which ultimately inhibit the 
transcription process of that DNA chain [132, 133]. Most NRTI drugs like 
dideoxynucleoside (ddNTPs) lack a 3’ hydroxyl group on the ribose sugar allowing 
them to act as chain terminators that block DNA synthesis which results into an 
abortive DNA replication and thus a disruption of the viral life cycle [132].  Currently, 
the Food and Drug Administration(FDA) approved drugs are Zidovudine (1-(3-Azido-
2,3-dideoxy-β-D-ribofuranosyl)-5-methylpyrimidine-2,4-1H,3H)-dione commonly 
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called AZT) Lamivudine, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-
1,2-dihydropyrimidin-2-one commonly called 3TC), Didanosine (9-[(2R,5S)-5-
(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one, commonly called ddI), 
Zalcitabine (4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1,2-
dihydropyrimidin-2-one commonly called ddC), Stavudine (1-[(2R,5S)-5-
(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-
dione commonly called d4T), Abacavir ([(1S,4R)-4-[2-amino-6-(cyclopropylamino)-
9H-purin-9-yl]cyclopent-2-en-1-yl]methanol commonly called ABC)), and  
Emtricitabine (4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-
1,2-dihydropyrimidin-2-one commonly called FTC)  see table 1 [134]. 
 
Figure 1.6 Structural formulas for some of the FDA approved NRTIs all designed to mimic 
physiological dNTPs.  
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1.6.3 Non-Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NNRTIs) 
Unlike the NRTIs, NNRTIs are not incorporated into the growing HIV-1 DNA strand 
but instead inhibit the HIV-1 reverse transcriptase (RT) by binding the hydrophobic site 
pocket located near the polymerase catalytic site in the p66 subunit of the RT. Drug 
incorporation  results in conformation changes of the RT that confers a significant 
reduction or complete halting of the polymerase activity [122, 135]. The limitation with 
this class of drugs is that slight variations in binding site (e.g. point mutation) can result 
in a significant impact of the drug’s sensitivity on the virus, giving these drugs a low 
genetic barrier.  They also exhibit a high level of cross resistance due to the narrowness 
of the binding pocket. Naturally, high drug resistance can easily and quickly develop 
for this category of drugs [136].   The current FDA approved NNRTIs are,  Delavirdine 
(N-[2-({4-[3-ylamino)pyridin-2-yl]piperazin-1}carbonyl)1H-indol-
5yl]methanesulfornamide, commonly called DLV) Efavirenz ((4S)-6-chloro-4-(2-
cycloro-4-(2-cyclopropylethynyl)-4-(trifluoromethynyl)-4-(trifluromethyl)-2,4-
dihydro-1H-3,1-benzoxazin-2-one, commonly called EFV), Etravirine (4-[6-Amino-5-
bromo-2-[(4-cyanophenyl)amino]pyrinmidin-4yl] oxy- 3,5-dimethylbenzonitrile, 
commonly called TMC125 and Nevirapine (11(-cyclopropyl-4methyl-5,11dihydro-6H-
dipyrodo[3,2-b:2’,3’-3e][1,4]diazepin-6-one, commonly called NVP) all of  which 
target the hydrophobic pocket of the HIV-1 reverse transcriptase.  
Stellenbosch University  http://scholar.sun.ac.za
26 
 
 
 
Table 1.1 Summary of FDA approved antiretroviral drugs arranged by classification [137] 
FDA Approved drug for HIV-1 treatment Year of FDA approval 
Nucleoside reverse transcriptase inhibitors (NRTIs)          
Year approved 
 
Abacavir (ABC)              
Didanosine (ddI)      
Lamivudine (3TC)  
Stavudine (d4T)   
Zalcitabine (ddC)  
Zidovudine (AZT, ZDV)   
Emtricitabine (FTC)   
Tenofovir (TDF)  
 
Nonnucleoside reverse transcriptase inhibitors 
(NNRTIs) 
Delavirdine (DLV)   
Efavirenz (EFV)   
Nevirapine (NVP)  
Etravirine (ETR)   
Rilpivirine   
 
Protease inhibitors (PIs) 
Amprenavir (APV)  
Indinavir (IDV)   
Lopinavir (LPV)   
Nelfinavir (NFV)   
Ritonavir (RTV)  
Saquinavir (SQV)  
Atazanavir(ATV)   
Darunavir (DRV)  
Tipranavir (TPV)   
Integrase inhibitors 
 Raltegravir  (RAL)   
Fusion entry inhibitors 
 Enfuvirtide (T-20)  
 Maraviroc (MVC)   
 
 
 
 
 
1998 
2000 
1995 
1994 
1987 
1987 
2003 
2001 
 
 
 
1997 
1998 
1996 
2008 
2008 
 
 
1999 
1996 
2000 
1997 
1996 
1995 
2003 
2006 
2005 
 
2007 
 
2003 
2007 
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1.6.4 Reverse Transcriptase Inhibitor (RTI) Drug resistance. 
The polymerase activity of the RT enzyme is in the p66 cleft of the p66/51 hetero-
dimer during transcription, the fingers and the thumb all work in unison to form a 
closed functional structure. Mutation in a number of the amino acid residues, most 
frequently in the palm and fingers, may result in a conformational change of the 
polymerase active site and consequently enzymes that can function better under drug 
pressure [123, 124].  Two types of drug resistance mutations have been categorized, 1) 
those that confer mutations that select for normal dNTP substrate incorporation against 
nucleotide analogs and, 2) those that confer mutations that enable the reverse 
transcriptase to excise nucleotide analogs. 
Examples of the first category include M184V, M184I (confer 3TC resistance), and 
E89G which have been reported to increase dNTP insertion fidelity as opposed to the 
nucleotide analogs [119-121]. Others including Q151M mutation have also been linked 
to multi–dideoxynucleoside resistance, [138] and L74V ddI that confers to ddI 
resistance [139]. M184 and Q151 are located within the 3’ hydroxyl terminus vicinity 
of incoming dNTPs and within the contact distance respectively. Mutation in these 
positions can alter the DNA conformation which in turn changes the dNTP geometry 
pocket and enables the RT to have increased fidelity for physiological dNTP as 
opposed to NRTI analogues [140].  This principle, confirmed in other studies, has 
shown  mutations such as E89G to result in an increased nucleoside insertion fidelity 
by 2-23 folds and 2-6 for the L74V associated mutation [139].  These findings 
considered together show that such mutations are able to alter the active site of the 
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reverse transcriptase in such a way that it discriminates between the normal dNTPs and 
the nucleoside analogs. 
Zidovudine (AZT) is probably the most well studied nucleoside analog in the second 
category above. Cellular enzymes convert AZT into AZT triphosphate (AZTTP), an 
analog product of deoxy-thymidine triphosphate (dTTP). During DNA replication, the 
reverse transcription gets aborted when AZTTP instead of dTTP is incorporated into 
the growing chain. AZT mutants however are able to discriminate against AZTTP by 
reversal polymerization of the terminal AZTMP to pyrophosphate (PPi) [141, 142].  
Polymerase residues that are affected during AZT resistance include positions L210W, 
T215Y/F and K219N of the palm and M41L, D67N and K70R of the fingers. All of 
these mutations are located further from the pol active site and are thought to exert their 
effect via alteration of the enzyme from a long range of conformational changes that 
reposition the active site aspartate residues [128, 143]. 
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1.7 STRUCTURAL FUNCTION OF HIV-PROTEASE 
 
HIV-1 protease is a homo-dimeric enzyme that consists of two identical ninety-nine 
amino acid monomers derived from protease cleavage of gag-pol polyproteins. The 
interaction of the two 99 amino acids form a tunnel in the interior that consists of two 
conserved sequence Asp-Thr-Gly that make up the enzyme active site. Primarily, the 
active site is formed by amino acid residues 25-32, 47-53 and 80-84. HIV-1 Proteases 
facilitate the viral particle’s maturation by cleavage of gag and gag-pol polyprotein at 
nine specific sites [144]  to yield functional enzymes and structural proteins necessary 
for the viral life cycle [145].  These enzymes, including integrase and reverse 
transcriptase, were discussed earlier [146-148]. 
In order for the gag-pol protein segment to access the protease active site for 
proteolytic cleavage, the protease flaps (two flexible domains thought to function as 
flaps) must open and undergo a dramatic conformational change to bind and close over 
the substrate sequence for cleavage [149].  Two Asp’s (D25) , one from each monomer, 
have been identified to be responsible for hydrolytically cleaving polyproteins that bind 
in the tunnel, through activation of a water molecule [149].  HIV proteases like plant 
Para retroviruses have aspartate proteinases similar to animal proteases such as pepsin, 
gastrin and renin and thus have been identified as aspartyl proteases [150]. See Figure 
1.7 for an illustration of HIV-1 protease structure. 
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Figure 1.7 above shows an inhibitor bound wild type HIV-1, three dimensional structure of   protease 
with lopinavir.  The white sticks show the active sites of the enzymes that comprise a conserved triad 
Asp-Thr-Gly at positions 25 to 27.  The flexible flaps of the enzyme that close down on the active site 
once the gag and gag-pol polyprotein is bound is located in residues 46-56 [151].  Figure adopted from 
Rhee, et al. [130]. 
Studies have shown that more than half of the residues in the protease can mutate in 
different combinations that could either reduce or improve the HIV-1 fitness against 
protease inhibitors [9, 152].   Protease mutations that occur within the substrate’s active 
sites have been termed “primary mutation” and their occurrence can directly reduce 
drug susceptibility.  On the other hand, the terms “secondary mutation” contribute to 
drug resistance by improving the HIV-1 replication fitness with a primary mutation 
[153]. 
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In one cohort that had 475 treatment naïve patients, researchers reported up to 69% 
conservation in five functionally important regions of protease which includes; the N 
terminal site (P1-P9), the C-terminal end (G94-F99),  the catalytic site (E21-V32), the 
protease flap (P44-V56), and the fifth contained in region G78-N88 [154]. In the same 
study, the researcher identified amino acids, L89, N88, I84, V82, T74, G73, H69, C67, 
Q61, D60, K55, I54, G48, M46, K43, M36, E35, D30, K20, and L10 as common 
polymorphism and drug treatment associated mutations in 639 drug treatment patients. 
Most of these mutations are located in peripheral areas of the enzyme preserving the 
active site region [154].  
Under PI drug pressure, most of the mutations initially selected are within the active 
site within the substrate cleft: R8, L23, D25-37, D29, D30, V32, I47, G48, I50, V82, 
and I84. In figure 1.7, this area is immediately around the pale yellow substrate.  
Mutations in this region have been termed primary mutations. Typical primary 
mutations include D30N, I50L/V, V82F/A/T, I84V and L90M [152].  Upon binding to 
the substrate or PI, the protease residue has been reported to rearrange residues either 
locally, such as in the flap regions or P1 loop, or in the entire protease to form a 
complete functional enzyme [155]. As such, a number of mutations outside the primary 
active sites have also been associated with the development of drug resistance during 
ART, most of which are in the sites mentioned before [154]. 
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1.7.1 Medical Implications 
Considering the important role that the protease enzyme has in the maturity of the HIV-
1 virus, a number of FDA approved drugs have been developed that aim to halt its 
functions.   Most of these drugs mimic the tetrahedral structures for the viral 
polyprotein intermediates of the hydrolytic reactions.   A drug interaction at the 
catalytic protease site  results in an inhibition of gag-pol polyprotein access to the 
active site and consequently viral maturity [156]. 
The main drawback, as was reviewed earlier, is that HIV-1, like other retroviruses, 
replicates and mutates extremely rapidly, resulting in mutants that deny protease 
inhibitors access to the active site. As was mentioned above, researchers have identified 
some significant amino acids in the wild genome and drug naïve patients, as common 
polymorphism sites during drug selective pressure.  Accumulation in a few numbers of 
such mutations on the functional parts of the enzyme could easily lead to drug failure 
[154]. 
At the time we conducted this study, Lopinavir/Ritonavir (Kaletra) was the most 
commonly used drug during second-line HAART in combination with two NRTIs in 
Zambia. This was in line with the recommendation by the Zambian Ministry of Health 
(MoH) guideline of 2007 for use of Lopinavir/Ritonavir, boosted Fosamprenavir, or 
boosted Atazanavir as anchor drugs in second-line HAART [157].  Lopinavir 
chemically designated (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-
hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide and 
molecular formula C36H48N4O5 see figure 1.8, is about 3 to 4 times more active than 
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Ritonavir but has poor bioavailability. Small doses of Ritonavir 1,3-thiazol-5-ylmethyl 
N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-
4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate 
(C36H48N6O5S2), drastically improves its bioavailability and hence the preferred 
combination as Kaletra [158].  A number of studies have shown this combination to be 
effective treatment both in treatment naïve and treatment experienced patients. For 
example, in a randomized open labeled study that compared Kaletra mono-therapy with 
Kaletra along with AZT and 3TC as initial treatment in treatment-naïve patients with a 
HIV-RNA < 100, 000 copies/ml,  triple therapy was reported to be superior p < 0.02 at 
48 weeks, with patients achieving virologic suppression [159]. A similar finding 
supporting superiority of triple therapy of Kaletra and two NRTIs compared to Kaletra 
mono-therapy was reported by Pulido et al 2008 [160]. 
In another study, Kaletra showed greater potency when compared with other PIs, either 
in treatment naïve or during salvage therapy for patients that had significant exposure 
to all other three classes of ART with virologic failure. About 76% of patients in this 
study reached viral suppression within 6 months, which is defined as a plasma viral 
load less than 500 copies/ml [161]. See figure 1.18 (a) (b) for the structural formulas of 
Ritonavir and Lopinavir respectively. 
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(a) 
 
(b) 
Figure 1.8 (a) Lopinavir, (b) Ritonavir, structural formula [162]. 
1.7.2 Drug resistance 
The Lopinavir/Ritonavir combination is characterized by a high genetic barrier to drug 
resistance and a better tolerance to poor adherence compared with earlier unbooted PIs 
[163]. A number of studies have reported Lopinavir/Ritonavir’s resilience against 
resistance during treatment. These include, one by Murphy et al, [164], in which they 
reported no clinical resistance in ART naïve patients treated with the  
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Lopinavir/Ritonavir based regimen for seven years. Saez-Llorens et al, 2003, reported 
similar results in pediatrics following treatment for 48 weeks [165]. 
Studies of Lopinavir resistance patterns conducted by Kempf et al. 2001 [166] , in 
patients failing treatment with other PIs, identified 11 amino acid position associated 
with reduced susceptibility. The positions included L10F/I/R/V, K20M/R, L24I, 
M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V, and L90M.  
Accumulation of more than 6 mutations showed a reduced virologic response, for 
example, mutations at positions 10, 54, 63, 71,82 and 84 were associated with 
relatively modest resistance (4 -10 fold) while a 20-40 fold phenotypic change was 
observed with mutation  K20M/R and F53L in association with any other one of the 11 
mutations identified earlier. Mutations at position 10, 54, 63, and 82 and/or 84, together 
with an average of three mutations at residues 20, 24, 46, 53, 71, and 90 showed a 20 
fold reduced susceptibility in the same study [166] and confirmed in another study 
[161]. Specific mutations, particularly I47A/V and V32I, have recently been associated 
with high levels of drug resistance to Kaletra [167]. The IAS-USA keeps updated lists 
of major and minor mutation associated with drug resistance.  Mutations associated 
with Kaletra resistance are shown in table 1.2 b.  
In the current study, we will determine the PI and RT mutation patterns in the Zambian 
population at the point of drug virologic failure which is defined as viral load greater 
than > 1000 copies during HAART in which Kaletra was used and compare them with 
PI naïve patients. 
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1.8 HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) 
RELATED RESISTANCE 
1.8.1 HAART treatment regimen 
According to the Zambian MoH antiretroviral therapy guide-line,[157] the following 
are the drug regimens for ART naïve adolescents: AZT + 3TC + EFV; AZT + 3TC + 
NVP; TDF + 3TC or FTC + EFV and TDF + 3TC or FTC + NVP for first-line therapy.  
For second-line therapy, if  d4T or AZT had been used in first‐line, TDF + 3TC or FTC 
boosted protease inhibitor (LPV/r and ATV/r) is used as the NRTI backbone in 
second‐line and if TDF was used in first–line, d4T or TDF + 3TC or FTC boosted 
protease inhibitor (LPV/r and ATV/r) is used as NRTI backbone in second‐line. Each 
of the drug categories is meant to inhibit a particular process of the viral replication and 
if properly used with drug resistance testing, can improve virologic outcome [104]. 
1.8.2 Drug failure associated mutation patterns during HAART. 
Mutations that are able to resist drug pressure inhibition are selected, and with time 
become dominant in the quasispecies population and continue crippling the host 
immune system by mainly deleting CD4+ T cells [84, 168].  The evolution of mutant 
viral population acquiring sufficient numbers of drug resistance mutations adequate to 
overcome antiretroviral activity has been referred to as “genetic drug barrier [169, 170]. 
Drugs that require multi mutations to occur on their target proteins before losing 
susceptibility are referred to as having a “high genetic barrier”. On the contrary, for 
some drugs, a single point mutation or two might be enough to alter susceptibility of 
HIV-1 ART. The latter is referred to as “low genetic barrier” [169]. 
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All NNRTIs generally have a low genetic barrier, for example, selection for the RT 
mutation K103N  results in NVP and EFV loss of susceptibility while RT mutation 
Y181C/I causes loss of susceptibility of all the currently available NNRTIs. NRTIs and 
PI drug combination however generally have a higher genetic barrier requiring multiple 
accumulation of mutation to render drug activity ineffective [15]. 
1.8.3 Genetic barrier in association with drug combination 
The likelihood of developing drug resistance also varies according to the drug 
combination used during therapy. Therefore a genetic barrier can also be defined in 
relationship with the drug combination rather than a single drug used during treatment.  
1.8.3.1 Low genetic barrier drug combinations with high virologic failure. 
There are number of drug combinations in this category. For example, Farthing and 
colleagues [171, 172]  were able to associate the TDF/3TC/ABC drug combination 
with early drug failure in an HIV-infected naïve patient pilot study. The mutation 
selected in this regimen mainly was M184V/I with 58% also containing nucleoside 
cross-resistant K65R viral isolates and no patient had K65R alone. The causes for 
earlier drug failure have been explored by other researchers as possibly being a result 
of: (1) possible negative drug-drug interactions between ABC and TDF, (2) a low 
genetic barrier to resistance posed by the regimen and (3) inadequate intracellular 
pharmacokinetic properties of 3TC and/or ABC when dosed once daily [173]. 
Other drug regimens with a low genetic barrier and high virologic failure include 
TDF/3TC/ddI, and TDF/ddI/EFV when used as initial treatment in HIV-1 antiretroviral 
naïve patients. The mutation selection for TDF/3TC/ddI combination seems to be 
similar with that described above for TDF/3TC/ABC with virologic failure observed by 
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12 weeks in HIV-1 antiretroviral naïve patients [172]. Single drug agent use of 3TC has 
been reported to select the M184V mutation of the RT that confers with high resistance 
capable of out populating the wild HIV strains in a few weeks [174] and almost always 
the earliest mutation to emerge when it is used in HAART [175, 176]. 
On the contrary, TDF/ddI/EFV treated HIV-1 antiretroviral naïve patients show a 
somewhat different mutation pattern than those described in the drug combinations 
above. A study by Leon and collegues [177]  accessing the use TDF/ddI plus EFV or 
nevirapine (NVP) detected K65R, L74V, L100I, K103N/R/T, Y181C and G190E/Q/S 
mutations at six months, arguing against the use of TDF and ddl when the third drug is 
an  NNRTI. 
1.8.3.2 Low genetic barrier drug combinations with high virologic success 
While a number of studies have reported on how some multi-drug combinations with 
low genetic barrier to resistance have a high drug failure [171, 172, 177], other studies 
have demonstrated higher rates of virologic success for the similar category of drugs. 
Some examples include drug combinations TDF + 3TC + EFV, ZDV + 3TC + EFV, 
and ABC + 3TC + EFV. 
In one particular study, Pozniak and colleagues [178], in a randomized, open-label, 
non-inferiority trial, reported a 62% viral suppression, that is, <400 copies/ml in the 
antiretroviral-naive patient group that received ZDV/3TC + EFV after 96 weeks of 
follow-up. ZDV has a wider genetic barrier and the use of thymine analogues with 3TC 
or FTC has been shown to delay emergency of the TAMs in the presence of M184V, 
3TC and FTC associated mutations.  Similary D4T+3TC and NVP or EFV have been 
shown to be effective during first-line therapy in treatment naïve patients with no 
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statistical difference between the groups with M184V being the most prevalent 
mutation selecting for the NRTIs [179, 180]. Most of first-line ART regimens used in 
Zambia are from this category of drug combination. 
1.8.3.3 HAART Regimens with High Genetic Barriers to Resistance 
Most PIs meet criteria of this group of drugs. Most of them have poor bioavailability 
and are used in combination with Ritonavir as was reviewed earlier to boost their 
efficiency.  
In HAART, the most used PIs in Zambia is boosted LPV (LPV/r) combined with two 
NRTIs. An example of such combination is d4T + 3TC + LPV/r. The combination was   
evaluated in treatment naive HIV-1 positive patients for a period of 24 to 108 weeks. 
This study showed no PI mutation upon treatment failure [181]. Another similar study 
was the SOLO study in which the researchers reported no PI mutation at 48 weeks after 
patient treatment with ABC + 3TC + FPV/r [182]. The tables 1.2 (a) (b) and (c) below 
summaries all currently known FDA drugs and associated resistance mutations. 
Stellenbosch University  http://scholar.sun.ac.za
40 
 
Table 1.2 (a) Summary of current HIV-1 mutations associated with drug resistance to FDA approved NRTI and NNRTI antiretroviral drugs. 
NRTI
Multi-nRTI Resistance : 69 insertion complex ( all affect nRTIs approved by USA FDA )
M41L A62V 69-inset K70R L210W T215YF K219QE
Multi-nRTI Resistance : 151 insertion complex ( all affect nRTIs approved by USA FDA except for Tenofovir)
A62V V75I F77L Y116F Q151M
Muilt-nRTI Resistance: Thymidine Analogue-associated Mutations (TAM; affect all nRTIs currently approved by the US FDA) 
M41L D67N K70R L210W T215YF K219QE
Abacavir K65R L74V Y115F M184V
Didanosine K65R L74V
Emtricitabine K65R M184VI
Lamivudine K65R M184VI
Stavudine M41L D67N K70R L210W T215YF K219QE
Tenofovir K70R
Zidovudine M41L  K70R L210W T215YF K219QE
NNRTI
Efavirenz L100I K101P K103 N/S V106M V108I Y181CI Y188L G190 S/A P225H
Etravirine V90I A98G L100I
K101 
E/H/P V106I
E138A 
G/K/Q V179DFT Y181CIV G190SA M230L
Nevirapine L100I K101P K103 N/S
V106 
A/M V108I Y181CI
Y188C 
L/H G190A
Rilpivitrine K101 E/P
E138AGK
QR V179L
Y181C 
I/V H221Y F227C M230IL
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Table 1.2 (b) Summary of current HIV-1 mutations associated with drug resistance to FDA approved PI antiretroviral drugs 
Atazanavir 
/rito navir L10I F/V/C G16E K20R M/I/T/V L24I V32I L33I F/V E34Q M36I /L/V M46 I/L G48V I5 0 L
Darunavir 
/rito navir V11I V32I L33F I47V I5 0 L
Fo s amprenav
ir /rito navir L10F /I/R/V V32I M46 I/L I47V I5 0 L
Indinavir 
/rito navir L10I R/V K20 M/R L24I V32I M36I M4 6  I/L
Lo pinavir 
/rito navir L10F /I/R/V K20 M/R L24I V3 2 I L33F M46 I/L I4 7  V/A I50V
Nelfinavir L10F I D3 0 N M36I M46 I/L
Saquinavir 
/rito navir L10F /I/R/V L24I G4 8 V
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Table 1.2 (b) Continued below, summarizes current HIV-1 mutations associated with FDA approved NNRTI antiretroviral drugs 
Atazanavir 
/rito navir D60E I62V I64 L/M/V A71 V/I T/L G73C S/T/A V82A T/F/I I84V I85V N8 8 S L90M I93L/ M
Darunavir 
/rito navir L7 6 V I8 4 V I89V
Fo s amprenav
ir /rito navir G73S L76V V82A F/T/S I8 4 V L90M
Indinavir 
/rito navir A71 V/T G73 S/A L76V V77I V8 2 A F/T/S I8 4 V L90M
Lo pinavir 
/rito navir L63P A71 V/T G73S L7 6 V V8 2 A F/T/S I84V L90M
Nelfinavir A71 V/T V77I V82A F/T/S I84V N88S /S L9 0 M
Saquinavir 
/rito navir I62V A71 V/T G73S V77I V82A F/T/S I84V L9 0 M
Tipranavir 
/rito navir H69 K/R T74P V8 2 L/T N8 3 D I8 4 V I89 I/M/V
 
Tables  1.2 (a) (b)  Shows  a summary for HIV-1 drug related mutations Amino acid abbreviations: A, alanine; C, cysteine; D, aspartate; E, glutamate; F, 
phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, 
threonine;V, valine; W, tryptophan; Y, tyrosine. Amino acids of the wild type are shown to the left of the amino acid position number and mutations on the right. 
Amino acids substitutions conferring resistance are shown in bold on the right of the amino acid position [183].
Stellenbosch University  http://scholar.sun.ac.za
43 
 
1.9 HIV DRUG RESISTANCE ASSAYS 
1.9.1 Introduction 
There are currently two types of drug resistance assays used for clinical practice. They 
are (1) genotypic assays which involve HIV-1 gene sequencing that identifies drug 
related mutation patterns and (2) phenotypic assays which are cell culture based in 
which viral replication is accessed in the presence or absence of drugs. The most 
preferred assays are population genotyping assays as they identify novel mutations as 
well as known mutations [184].   Most of these assays detect HIV resistance by 
targeted sequencing of the protease (PR, amino acids 1-99) and reverse transcriptase 
(RT, amino acids 1-320) in the pol gene of HIV as drugs that target these proteins as 
the most abundant of the FDA approved.  The drawback is that currently the only two 
FDA approved commercially available assays, ViroSeqTM HIV-1 Genotyping Version 
2.7 (Applied Biosystems, Foster City, CA, USA) and TruGene (Siemens, Deerfield, IL 
USA), are too costly for most developing countries where HIV prevalence is highest 
[185]. 
1.9.2 In-house HIV-1 genotyping assay. 
In-house assays, which can be up to three times cheaper than commercial kits, offer a 
more feasible approach to drug resistance testing in resource constrained countries. 
Some researchers have also found the in-house assay to be more sensitive than the two 
commercially available drug resistance genotyping assays mentioned earlier. These 
reports have been particularly so when using “in-house” assays, designed for non-
subtype B HIV-1 testing in non-subtype B populations [185, 186].  When evaluated 
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against commercial kits, blinded quality assurance programs have indicated high 
concordance between in-house methods and kits [187, 188]. 
Findings from studies such as the ones described above show that HIV-1 subtype B 
strains represented only 12% of the global infections.   Subtype C accounted for 50% 
(most prevalent strain in sub-Sahara) of all infections worldwide while Subtypes A, D 
and G accounted for 12%, 3% and 6%, respectively [25]. Other subtypes F, H, J and K 
together only accounted for 0.94% of infections by the end of the same year. The 
recombinant forms of the virus all together accounted for about 18% of the worldwide 
infections [25].  HIV-1 subtype C is the most prevalent subtype in Zambia [189]. 
Studies have shown that about 80% of patients who fail ART have drug resistance due 
to HIV-1 mutation [190]. It is therefore important that genotyping assays used to 
monitor these changes have high sensitivity.  Both TRUGEN and ViroSeq genotyping 
assays do not genotype the HIV-1 subtype C as well as they genotype the HIV-1 
subtype B as they have been optimized for genetic subtype B strains [191, 192].  In one 
study, investigators were only able to successfully sequence 69% of the samples and 
only 64% in another study with these commercial assays on non-subtype B strains. An 
HIV-1 subtype C specific genotyping assay with a sequencing rate greater than 80% 
needs be used to monitor viral mutation to help in clinical management [184]. An 
epidemic of HIV drug resistant strains can easily develop in patients with better access 
to antiretroviral drugs but with inadequate monitoring due to a widespread of resistant 
strains [186]. In a VIRAD APT randomized controlled trial carried out in  France, 
researchers were able to show the benefit of genotypic-resistance testing in  clinical 
monitoring of treatment [193]. 
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Many researchers have thus developed affordable assays costing up to four times less, 
but with an equivalent or higher sensitivity than commercial kits in an attempt to 
increase accessibility of drug resistance assays in resource limited countries [184, 186]. 
Finding from studies such as the ones described show that due to the high rates of 
replication errors, and development of drug resistance during therapy, it is important 
that HIV-1 genotypes are determined before or during ART in patients for better 
clinical management. Knowing the prevalence of such mutations within a population 
could equally be helpful to clinicians in deciding a drug regimen for patients without an 
HIV genotype result. Such data is limited in the Zambian population mainly due to the 
high cost of performing HIV-1 genotyping in infected patients.  
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1.10 AIMS OF THE STUDY 
 
The aims of the current thesis were to: 
1) Develop in-house assay as an economical alternative to commercial assays. 
2) Validate the in-house assay using a clinically relevant population for the 
mutations and resistance. 
3) Describe the frequency of reverse transcriptase and protease mutation among 
patients failing first-line and second-line therapy in Zambia.  
Hypothesis 
We hypothesize, in a Zambian population, patients on second line HAART who are 
treated exclusively with the Lopinavir/Rotinavir Protease Inhibitor would not have 
selected for Lopinavir/Rotinavir drug resistance mutations at treatment failure. 
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2.0 CHAPTER 2: MATERIALS AND METHODS 
2.1 STUDY DESIGN 
2.1.1 Patient sample and testing. 
Patient’s whole blood, n=43, (19 were on first-line regimen and 24 on second-line 
regimen) was collected from those who were failing HAART, defined as having a viral 
load > 1000 copies/ml despite treatment. Clinicians in various clinics in Lusaka 
determined which patients met the criteria. The clinics included, Kamwala, Matero, 
Chipata, Kabwata, Makeni, Chelstone, Kanyama, Chawama, Kalingalinga, and 
Mutendele. We separated plasma from whole blood by centrifugation (eppendorf 5810, 
Germany), within 4 hours of collection. Plasma was aliquoted into Rnase-free 2ml vials 
and stored at -65oC to 80oC until use.  
Viral load was re-tested using Abbott m2000 real time PCR technology to confirm 
virologic failure. Samples with a viral load greater than 1,000 copies/ml were selected 
for HIV drug resistance testing. 
Unless requested by the clinician at the time of drug resistance testing, CD4 results 
used in the study was the most recent test on the patient’s file. CD4+ lymphocytes from 
peripheral blood was counted by flow cytometry (Coulter XL; Coulter Co., Hialeah, 
FL), using a pan leucocyte gating (PLG) method [194]. 
HIV-1 viral RNA was manually isolated using QiaAmp Viral RNA mini kit.  Roche 
expand reverse transcriptase and Expand DNA polymerase were used to perform 
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reverse transcription and PCR respectively. Chain termination cycle sequencing PCR 
was done using Applied Biosystem BigdyeTeminator kit and sample sequencing in an 
ABI 3101xl genetic analyzer.  
Sequence analysis was done using sequencer software version 4.10.1 and drug 
resistance determined by submitting sample sequences to the online Stanford HIV data.  
Figure 2.1 illustrates the study design.  
Ethical clearance for the use of patient sample material was obtained through the 
University of the Zambia Biomedical Research Ethical committee (ethics clearance 
number: FWA00000338, IRB00001131 of IORG000774. 
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Figure 2.1 Schematic representation of the study design 
 
Samples drawn from a patient’s failing 
HAART,  
N= 43 
- Viral load test repeated using the 
AbbotM2000 RT-PCR 
- Plasma aliquot stored at -70 oC 
until genotyping is performed. 
- PCR product detected using 
agarose gel electrophoresis. 
Samples without product 
repeated once. 
- Product concentration 
determined by nano-drop 
spectrophotometery. 
Genotype analysis 
- Sequencher software version 4.10.1 
Drug mutation profile analysis 
- Online Stanford HIV database analysis tool 
EDTA plasma separated from cells within 
four hours of blood draw 
Manual RNA extraction (QiaAmp KIT), 
Reverse Transcription (RT) and PCR done on 
samples with VL equal or greater than 
1000cps/ml 
In few cases, sample could be processed 
without repeat VL (if patient had VL test 
>10 000 copies within a 2 weeks period) 
Amplicon purified/Sequencing PCR 
/sequence electrophoresis using ABI 
3130xl analyzer. 
List of RTI drugs accessed for 
resistance 
NRTI                      NNRTI 
3TC, AZT               Ritivitrine 
ABC, D4T               EFV, ETR  
List of PI accessed 
ATV/r       TPV/r 
 DRV/r      SQV/r 
FPV/r        NFV 
IDV/r         LPV/r  
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2.2 HIV-1 GENOTYPING ASSAY 
2.2.1 Introduction  
The HIV-1 Genotyping System is intended for use in detecting HIV genomic mutations 
that confer resistance to specific types of antiretroviral drugs, as an aid in monitoring 
and treating HIV infection. As was stated earlier, two commercial kits with FDA 
approval (TRUGENE and ViroSeq) can be used to genotype HIV-1 for the following 
purposes: (1) Detect HIV-1 Subtype B viral resistance in plasma samples collected in 
EDTA with a viral load ranging from 1000 to 750,000 copies/mL and (2) Genotype the 
entire HIV-1 protease gene from codons 1-99 and two-thirds of the reverse 
transcriptase (RT) gene from codons 1-321. In this study, an in-house assay adapted 
from, Wallis et al was used [184]. 
2.2.2 Assay design 
Genetic analyses of the HIV-1 plasma-derived pol gene was done using reverse 
transcriptase polymerase chain reaction, polymerase chain reaction (PCR) and 
genotyping PR (amino acids 1-99) and RT (amino acids 1-321) [184]. As was 
mentioned earlier, HIV-1 replicates using the virally encoded RT which contains a 
catalytically active larger unit (p66) and a smaller subunit (p51). The assay was 
designed to capture only the PR gene and the subunit of the p66 which comprises the 
DNA polymerase (1-321) [124] to which most of the RT inhibitors target.  The other 
residues of p66 include connection domain (322-440) and the ribonuclease (Rnase) H 
(441-560) domain [124, 195]. As was previously stated, Rnase activity is responsible 
for the degradation of RNA of the RNA/DNA hybrid, an important stage in the 
conversion of single stranded RNA to proviral DNA [196]. The figure below 
summarizes the assay design. In (A) the red bar shows the portion (2047-3610) of the 
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9719kb HIV-genome targeted by our PCR primers and in (B), is an illustration of the 
primer design. At the bottom of the red bar are the two PCR primers and at top are the 
six primers used for sequencing. Note that primer RWF2 (P21) was only used as 
backup primer if quality of the overlapping portions of primers CWS1, CWS2, CWS3, 
and CWS4 and CWS5 came out poorly. 
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Figure 2.2 The top (A) shows the liner genome of HIV-1. The solid grey block shows regions of that 
genome that encodes for various proteins. The top scale shows the start position for various genes while 
the bottom scale shows the gene stop locations. The red blocks indicate base position 2047-3610 of the 
Pol gene (B); the solid red block is a part of the pol gene magnified from (A); to illustrate primer design 
for RT/PCR and sequencing;  orange arrows show reverse or antisense primers while the green arrows 
depicting the forward or sense primers (B). All the arrows above the pol gene (red block) P21, P41, P42, 
P43, P44 and P45 are for sequencing while the ones below (CWF-1 and CWR-1) are for RT/PCR. Figure 
2.2 (A) was generated online using a Los Alamos National Laboratory (LANL) HIV sequence locator 
tool. 
 
2.2.3 RNA Isolation. 
Whole blood samples were collected in EDTA containers at the clinics, and sent to the 
laboratory within two hours of collection. Plasma was immediately separated from cells 
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using an AllegraTM X22R Beckman centrifuge (Beckman coulter, CA Germany) at 
1000xg for 15 minutes and aliquoted in 2ml Rnase free vials.  Plasma was then stored 
between -65oC to 80oC until use. 
To isolate RNA, 500l of thawed plasma was ultra-spun at 21 000xg in an AllegraTM 
X22R Beckman centrifuge (Beckman coulter, CA Germany), at 4oC for one hour in 
2ml vials. This was done to concentrate nucleic acid to the bottom pellet that forms. 
360 l of supernatant plasma was removed from vials within 5minutes, avoiding 
touching the pellet which was then re-suspended in the remaining 140l plasma. The 
140l of plasma was then treated as a start sample and RNA was extracted using 
QiaAmp Viral RNA mini kit (QIAGEN technology, USA) as per manufacturer’s 
instructions. 
2.2.4 HIV-1 Reverse Transcription  
Extracted viral RNA was synthesized into cDNA using the reverse primer CWR1 (5’-
GCA TAC TTY CCT GTTTTC AG-3‟; HXB2 nucleotide position 3610to 3594) and 
the Expand Reverse Transcriptase (RT) kit (Roche Diagnostics, Germany). For each 
sample, including negative and positive controls, 8l of extracted RNA was incubated 
with 2.5l of 20M CWR1 oligonucleotides in THERMOCYCLES at 65oC for 10 
minutes. The samples were immediately transferred to ice after incubation period and 
9.5 ml of reaction master mix added in each.  See Table 2.1 for master mix preparation. 
The reaction tubes were then incubated at 42oC for one hour (Table 2.2). 
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Table 2.1 Reverse transcriptase reaction concentrations. 
Reagent Volume for n=1  (l) Concentration Manufacturer 
5X RT Buffer 4 1X Roche, MA, German 
DTT 2 - Roche, MA, German 
dNTP (10mM) 2 1mM Roche, MA, German 
RNAse Inhibitor (5000U) 0.5 125U Roche, MA, German 
Expand RT 1  Roche, MA, German 
Final volume 9.5   
 
Table 2.2 Reverse transcription incubation conditions 
Temperature (oC) Time 
65 10 min 
42 60 min 
4 ∞ 
 
2.2.5 Polymerase Chain Reaction. (PCR) 
Amplification was performed using primers CWF1 (5’-GAA GGA CAC CAA ATG 
AAA GAY TG-3’; HXB2 nucleotide position 2047 to 2066) and CWR1 and 20μl of 
synthesized cDNA with the Expand High FidelityPLUSkit (Roche, Germany). The PCR 
master mix was prepared as per manufacturer’s instructions (Table 2.3), [184]. The 
cycling conditions (GeneAmp PCR system 9700, Applied Biosystems, Foster City, 
USA), consisted of an initial denaturizing step of 94oC for 2 minutes, followed by 10 
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cycles of 94oC for 30 seconds, 54.5oC for 30 seconds and 72oC for 2 minutes and then 
35 cycles of 94oC for 30 seconds, 55oC for 30 seconds and 72oC for 2 minutes 
increasing by 10 seconds each cycle, and a final elongation step of 72oC for 10 minutes 
[184]. 
Note that all PCR and sequencing primers were designed from the 2004 consensus 
HIV-1 subtype C sequence available on the Los Alamos Database 
(www.hiv.lanl.gov/).[184] 
Table 2.3 PCR reaction mixture. 
Reagent Volume for 1 sample 
(l) 
Final concentration in 
50ml 
Manufacturer 
5X Buffer 10 1X Roche, USA 
10mM dNTP 1 0.2M Roche, USA 
20mM CWR-1 1 0.4M Roche, USA 
20mM CWF-1 1 0.4M Roche, USA 
Expand polymerase (250U) 0.5 2.5U Roche, USA 
DEPC free Rnase free 
Water 
33.5 - Ambion, TX, USA 
Total 47.0 -  
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2.2.6 Gel Electrophoresis 
Successful PCR of samples was determined by electrophoresis and UV light (302nm) 
visualization of DNA bands on a solid 0.8% molecular grade agarose gel (Bio-Rad, 
USA) which was prepared in a 1X 89mM Tris, 89mM boric acid, 2mM EDTA buffer 
(TBE), (fermentas USA) and 0.g/ml ethidium bromide. To prepare a 0.8% gel, 0.8 
grams of agarose was weighed on a digital scale (Mettler Toledo, Canada) and 
dissolved in 100mls of 1X TBE buffer. The mixture was heated to boil in a microwave 
and was allowed to cool to about 60oC. 5l of 10mg/ml ethidium bromide was then 
added to the gel, which was poured into a molding tray containing a 1.5mm x 30 comb. 
The gel was allowed to solidify at room temperature between 15 and 30 minutes and 
then the comb was removed, creating wells. 
A DNA lambda DNA/HindIII marker, 2 (thermo fisher, USA) was prepared as per 
manufacturer’s instruction and 5ml loading in the first well. 5 ml amplicon for the test 
samples was mixed with 1ml 6X loading dye and then the mixture was transferred in 
the gel. Electrophoresis was the performed as a constant voltage of 80 for 45 minutes. 
Bands were then visualized using a MultiDoc digital imaging system (Cambridge, UK).  
The run was considered invalid if a band was detected in the negative control sample.  
2.2.7 PCR products Purification and concentration determination 
All samples which showed a successful PCR on gel (approximately 1.5 kb in length) 
were purified and concentrated in micro columns using the GFX DNA gel purification 
kit (AEC Amersham, UK) to remove any unreactive substances such as 
oligonucleotides and DNA polymerase. A total of 60l was eluted. 
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1l to 2l was used to determine sample concentration using a nanodrop 
spectrophotometer and diluted according to their concentration to 10-14ng/l. Any 
sample that had a concentration below 5ng/ml was re-amplified to increase the 
concentration as the PCR procedure stated earlier.  
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2.2.8 Chain termination PCR and sequencing (Cycle sequencing) 
Sequencing was performed using 3.2pmol each of five sequencing primers (CWS1: 
5’CCTCAAATCACTCTTTGGC-3’; HXB2 nucleotide position 2253 to 2271; CWS2: 
5’AGAACTCAAGACTTTTGGG-3’; HXB2 nucleotide position 2796 to 2814; CWS3: 
5’TGCTGGGTGTGGTATTC-3’; HXB2 nucleotide position 2846 to 2830; CWS4: 
5’TCCCTGTTCTCTGCCAATTC-3’; HXB2 nucleotide position 3472 to 3453; CWS5: 
5’TGGTAAATTTGATATGTCCATTG-3’; HXB2 nucleotide position 3577 to 
3555[184], and one additional primer not used by wallis et al. P21: 
5’GGAGGTTTTATCAAAGTAAGACAGTATGA-3; HXB2 nucleotide position 2403 
to 2432, 11μl (8-12ng/dl) of purified PCR product, 0.5x BigDye® Terminator v1.1/3.1 
Sequencing Buffer and 0.5x Ready Reaction Premix from the ABI PRISM® BigDye® 
Terminator version 3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, 
USA) in a total volume of 20μl, with standard cycle sequencing conditions as per 
manufacturer’s instructions[184]. Unincorporated ddNTPs were then removed by 
precipitation with ethanol-sodium acetate, method, and then the dried pellet was re-
suspended in 20μl Hi-DiTM Formamide (Applied Biosystems, UK). Sequence data 
was obtained using an ABI 3130xl genetic analyzer, (Applied Biosystems, Foster City, 
USA) and edited using the Sequencing analysis 5.3.1. Program (Applied Biosystems, 
Foster City, CA, USA).Sequence data was further edited using Sequencer 4.10.1 (Gene 
codes, cooperation, MI, USA) and primary mutations (PRMs) that are associated with 
drug resistance to PR and RT were detected by means of Stanford University calibrated 
resistance tool online. 
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To perform chain termination sequencing PCR (cycle sequencing), reagents were 
prepared as shown in table 2.4 below for each reaction.  
Table 2.4 Cycle sequencing reaction concentrations. 
Reagent Volume for 1 sample 
(l) 
Final concentration 
in 50ml 
Manufacturer 
BigBye ready  reaction 
Premix (2.5X) 
4 0.5X AB* 
BigDye® Terminator 
v1.1/3.1 Sequencing Buffer 
2 0.5X AB* 
 
3.2M Primer  
 
1 
  
DNA sample 11  INQ** 
    
DEPC free Rnase free 
Water 
 
2 
- Fermentas*** 
Total 20l -  
*Applied Biosystems UK. **Inqaba biotec, SA. *** Ferments MD, USA,  
 
To purify with Ethanol/sodium acetate, 2l of 3.0M sodium acetate, pH 5.2 was added 
to 50l of 100% ethanol to mark working reagent. The total was added into each 
sequencing reaction and plate centrifuged 20 minutes at 2000 x g.  The plate was 
immediately inverted without disturbing the pellet as soon as centrifuge had stopped 
and centrifuged at 150 x g for 1 minute to remove the supernatant. 150ml of 70% 
freshly prepared ethanol was added to each reaction and the plate centrifuged at 2000 x 
g for 5 minutes and supernatants removed as described before. Pellets were dried for 
about 5 minutes and re-suspended in 20l Hi-DiTM formamide (Applied Biosystems, 
UK). 
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2.3 HIV-1 GENOTYPING ASSAY 
2.3.1 Parallel testing  
Seven samples were sent to the University teaching hospital in Zambia for genotyping using 
the commercial ViroSeq kit. We tested the same samples with the in-house kit, using the 
method as described above and the sequences were compared at the nucleotide and 
mutation level to determine the level of incongruity between the consensuses. 
2.3.2 Accuracy and reliability assessment of assay.  
Five samples were run on the ABI3130XL and repeated a minimum of three times. 
Sequences were compared at a nucleotide and mutation level to determine the level of 
incongruities between the consensuses. 
2.4 DATA ANALYSIS: 
2.4.1 Parallel testing 
To define genotypic correlation between the in-house and viroseq assays, complete in-
house, tested parallel sequences (n=7), encompassing the pol region of interest were 
assembled and manually edited using Sequencher version 4.10.1 (Genecodes, MI,USA) 
to generate consensus sequences which were compared with those from the parallel 
assay. BioEdit version 7.0.9 analysis tool software, (NC, USA) was used to generate 
phylogenetic trees to ensure there was no cross-contamination of samples. 
Both ViroSeq and “in-house” consensus sequences were submitted to the Stanford 
Database (http://hivdb.stanford.edu/),   to generate an HIV-1 drug resistance mutation 
report, and also submitted to the REGA sub-typing tool, 
(http://dbpartners.stanford.edu/RegaSubtyping/) to determine HIV-1 subtypes. The 
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University of Stanford HIV drug resistance database utilizes known HIV-1-B wild type 
genetic sequences maintained at the Los Alamos HIV Sequence Database (hiv-
web.lanl.gov) to determine base substitutions in submitted consensus sequences which 
acts as the non drug resistant control. 
Sequence similarity between the two corresponding samples was done by submitting 
their protease and RT sequences online at the bioinformatics Institute website clustalw2 
tool (http://www.ebi.ac.uk/Tool/msa/clustalw2/) which aligns sequences for ease of 
comparing.  Hamming distances of the corresponding samples were calculated 
manually to determine congruence. The hamming distance was calculated by 
computing percentage of the total nucleotide mismatches and partial mismatches 
(mixtures) divided by total nucleotides compared. A hamming distance of ≥98% was 
considered acceptable, indicating high sequence similarity. 
Samples between the two laboratories were compared at the nucleotide and mutation 
level to determine the level of disagreements between the consensuses: a) total number 
of errors in a sequence was accessed; b) number of mismatches between the two 
methods was compared.  There are three types of mismatches: partial (R vs. G), 
complete (A vs. G), and data missing (N), see Table 2.5 below for IUPAC nucleotide 
codes.  For our analysis only complete and partial mismatches were investigated; c) the 
mutation lists were compared. 
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Table 2.5 IUPAC Nucleotide code. 
IUPAC nucleotide code Base 
A Adenine 
C Cytosine 
G Guanine 
T (or U) Thymine (or Uracil) 
R A or G 
Y C or T 
S G or C 
W A or T 
K G or T 
M A or C 
B C or G or T 
D A or G or T 
H A or C or G 
V A or C or G 
N Any base 
. or - Gap 
 
2.4.2Assay specificity  
All five samples used for this purpose were analyzed exactly as mentioned above in 
section 2.4.1, and similarly compared between runs. 
2.4.3 Statistical analysis.  
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A contingency table in GraphPad Prism5 statistical software was used to determine the 
prevalence of drug resistance mutations between samples from patients on first and 
second-line therapy drug regimens and reported with 95% CIs based on a normal 
approximation of binominal distribution. The numbers of NRTI, NNRTI and PI drug 
resistant mutations in both groups were reported and their associations were tested 
using Fisher’s exact test. All tests were 2-sided and P value was statistically significant 
if alpha <0.05.  
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3.0 CHAPTER 3: RESULTS 
3.1 GEL ELECTROPHORESIS. 
All sample’s amplicons were visualized on a 1% gel prepared with 5g/ml 
concentration ethidium bromide as was described in the Materials and Methods section. 
Following electrophoresis at constant voltage of 80, bands were visualized with  UV 
light and picture taken. In figure 3.1, a representative example of one run is shown: 
sample migration was from top (cathode) to bottom (anode). On the far left, in the first 
well was the lambda DNA/HindIII marker2 mass ladder. Our bands of interest were 
about 1500bps in size and are seen slightly above the 2027 position of the ladder for the 
next 9 samples toward the right; see ruler on the far right in black and white for size 
reference. 
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Figure 3.1 A representative example of one gel electrophoresis result of 10 samples following PCR. Gel 
and sample were prepared and loaded on the gel as was described in the Material and Methods section. 
From your left, in the first position is the Mass ladder (lambda II ) followed by a Positive control sample. 
The interpretation of the mass ladder can be seen one the scale on the furthest right.  Positions 3 to 8 
indicate patients sample and in position 9, negative control.  
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3.2 SEQUENCING  
Each sample was cycle sequenced in aliquots of five 11ml per primer as described in 
the material and methods section and capillary electrophoresis was performed in a 20l 
Hi-DiTM Formamide suspension.  Sequences were aligned and overlapping sequences 
connected using the Sequencher 4.10.1 software, figure 3.2.  In the same figure, the 
deep green thick bar indicates the region of PR and RT that was adequately covered by 
primer sequence run in both directions. The light blue color on the same bar on both 
ends show regions where sequencing primers did not overlap. 
Figure 3.3 is an extraction from Sequencher 4.10.1, of a picture showing 
electropherograms of nucleosides (bases): adenine, A, in green, thymidine, T, in red, 
guanine, G, in black and cytosine, C, in blue. The figure shows segments (A), (B) and 
(C) of regions analyzed for sample 130-08810-7 covering PR and RT gene. Two mixed 
bases calling in (A) and (C) for cytosine or adenine and adenine or guanine respectively 
are called M and R as per IUPAC codes respectively. Finalized edited sequences were 
used to generate a single complete consensus sequence for each sample, see 
appendices.  
Phylogenetic trees were produced on Bioedit using consensus sequences for each 
sample to determine their similarity within the HIV-1 clades, see figure 3.4. 
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 Figure 3.2  A represatative result of one the samples tested (200-05086-9) showing muiltple primer alignment to form a continues PR/RT gene fragement.  The red 
dotted lines show the coverage of three reverse primers, CWS3 (P43), CWS4 (P44) and CWS5 (P45); the green arrows indicate region covered by the Forward primers 
CWS1 (P41) and CWS2 (P41). Figure generated using sequencher 4.10.1  
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(A) (B) (C)  
 
 
 
Figure3.3 A representative sample.  Eletropherograms extracted at 3 different locations of the pol gene segments. Electropherograms for bases A, C, G and T are 
shown in colors green, blue, black and red respectively: (A) Shows the first 12 start sequences covered by only one primer. (B) Shows positions between 247 and 260 
of the protease region. Mixture nucleotide in red (M) was manually edited representing either C or A. (C) Shows positions between 810 and 824 of the protease/RT 
region (position 513-527 of RT). Mixture nucleotide in red (R) was manually edited representing either A or G. The figure was generated using Sequencher s version 
4.10.1 software  
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Figure 3.4  Phylogenetic tree analyses of 43 samples constructed using HIV RT and PR amino acid sequences. The alignment and the phylogenetic analysis were done 
using bio-edit software version 7.0.9.  The scale bar indicates the evolutionary distance of 1% nucleotides per position in the sequence. 
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3.3 HIV-1 ASSAY VALIDATION 
In order to validate the in-house genotyping assay, we compared 7 samples with results 
obtained using a commercial and FDA approved kit, viroseq. Sequences were aligned 
by the clastaw2 tool of Bio-edit version 7.0.9 software, figure 3.5 and nucleotides 
manually compared. Hamming distances were calculated and all samples were found 
comparable (Table 3.1). The minimum hamming distance was 99.54%. No complete 
nucleotide mismatches were found between samples 0A UTH and 0A CIDRZ, 0B UTH 
and 0B CIDRZ, 0C UTH and 0C CIDRZ, 0E UTH and 0E CIDRZ. Five, zero, four and 
four partial mismatches were observed for the same pairs respectively. Two, five and 
one complete mismatches were observed between samples, 0F UTH and 0F CIDRZ, 
0G UTH and 0G CIDRZ, 0D UTH and 0D CIDRZ respectively. We observed three, six 
and one partial mismatches in the pairs respectively. All samples showed 99.2% 
similarities in the amino acid translation. 
In order to determine assay reproducibility, 5 samples were repeated 3 times each and 
nucleotides compared manually and sequences analyzed as stated above. The minimum 
hamming distance was 99.52%.  We observed no complete mismatched mutation in all 
the five repeated sequences and a 100% similarly in amino acid translation, see Table 
3.2 for a summary. 
Phylogenetic relationships of unambiguously aligned nucleotide sequences for both 
experiments representing the reverse transcriptase and protease enzymes of the pol 
gene are shown in figures 3.6 and 3.7. The alignment and the phylogenetic analysis 
were done using bio-edit version 7.0.9 software as indicated in the material and 
methods section. The scale bar represents nucleotide substitutions per site.  
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Figure 3.5 shows aligned, sample sequences used in parallel assay validation.  These were used for nucleotide comparison between sequences to determine the level of 
similarity or incongruity between the consensuses.  European Bioinformatics institute online software was used for sequence alignments.
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Table 3.1 Parallel validation. 
PID Length 
compared
Reference 
sequence
complete 
Mismatched
Partial 
Mixture
Hamming 
distance (same; 
≥98%)
Subtype
OA-CIDRZ 1173 OA-UTH 0 5 99.57% C
OB-CIDRZ 1186 OB-UTH 0 4 99.66% C
OC-CIDRZ 1224 OC-UTH 0 0 100.00% C
OD-CIDRZ 1178 OD-UTH 1 6 99.41% C
OE-CIDRZ 1205 OE-UTH 0 4 99.67% C
OF-CIDRZ 1088 OF-UTH 2 3 99.54% C
OG-CIDRZ 1265 OG-UTH 5 1 99.53% C  
Table 3.1 above and  3.2 below  shows the results of parallel testing results for the 7 samples (CIDRZ) 
tested with the “in-house” genotyping assay compared with 7 (UTH) corresponding reference sequences 
previously genotyped using Viroseq Kit. Table 3.2 shows a summary of reproducibility results 
comparing a minimum of 3 sequences. Hamming distances for both experiments were calculated for the 
Protease and RT p66 genes and the Rega HIV-1 subtyping tool (http://hivdb.stanford.edu) was used to 
assign the HIV-1 subtype for the patients  
Table 3.2 Reproducibility  
PID Length 
compared
Reference 
sequence
complete 
Mismatched
Partial 
Mixture
Hamming 
distance 
(same; 
≥98%)
Subtype
190-05223-2 1208 190-05223-2 0 1 99.92% C
190-05223-2 1208 190-05223-2 0 3 99.75% C
190-05223-2 1208 190-05223-2 0 3 99.75% C
025-12099-1 1212 025-12099-1 0 0 100.00% C
025-12099-1 1212 025-12099-1 0 2 99.83% C
40200-B 1166 40200A 0 0 100.00% C
40200-C 1166 40200A 0 3 99.74% C
ZamB 1258 ZamA 0 6 99.52% C
ZamC 1258 ZamA 0 5 99.60% C
200-04515-5 1190 200-04515-5 0 0 100.00% C
200-04515-5 1190 200-04515-5 0 2 99.83% C
200-04515-5 1190 200-04515-5 0 2 99.83% C
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Figure 3.6  Phylogenetic relationships of 7 unambiguously aligned nucleotide sequences representing the reverse transcriptase and protease enzymes of the pol gene of 
the HIV-1C. The alignment and the phylogenetic analysis were done using bio-edit software version 7.0.9. The scale bar indicates the evolutionary distance of 1% 
nucleotides per position in the sequence.
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Figure 3.7 Phylogenetic relationships of 5 unambiguously aligned nucleotide sequences representing the reverse transcriptase and protease enzymes of the pol gene of 
the HIV-1C. The alignment and the phylogenetic analysis were done using bio-edit software version 7.0.9. The scale bar indicates the evolutionary distance of 1% 
nucleotides per position in the sequence.
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3.4 GENOTYPIC DRUG RESISTANCE TEST RESULTS. 
The table 3.3 below shows the characteristics of patients at the time point that the 
patient samples were analyzed. 37% patients in this study were male. Apart from two 
patients with HIV-1 subtypes K and 06_CPX, all the other patients were infected with 
HIV-1 subtype C. The median CD4 count within < 6 months at the time of the study 
was 133 cells/mm3 (interquartale range, IQR, 2-430 cells/mm3). The median HIV-1 
RNA count within at the time point of the study was 5.3x104 copies/ml (interquartale 
range, IQR, 1.0x103 – 8.7x105 copies/ml.  
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Table 3.3 Characteristics of study population. 
Characteristic Patients n=43 First-line 
regimen (n=19)
Second-line 
Regimen (n24)
P
Age, median Year (IQR) 39 (11-73)
Male sex 16(37%)
Black race 43
CD4 cell count, median cell/mm3 (IQR) ≤6months 133 (2-430)
Plasma HIV-1 RNA level, median log10 copies/mL 5E+04 (1E+3 to 8E+5)
Duration on HAART, median years (IQR) 42(12-72) 60(12-108)
Duration on Second-line regimen, n=24, median 
months (IQR) 12(12-72)
Regimen: First-line Regimen
AZT+3TC+NVP 3(16%) 11(45%) ns
AZT+3TC+EFV 1(5%) 6(25%) ns
D4T+3TC+NVP 10(53%) 9(38%) ns
D4T+3TC+EFV 1(5%) 1(4%) ns
TDF+3TC+NVP 4(21%) 5(21%) ns
TDF+3TC+EFV 2(11%) 0 ns
TDF+FTC+EFV 4(21%) 2(8%) ns
TDF+FTC+NVP 0(0%) 3(13%) ns
ABC+3TC+NVP 1(5%) 1(4%) ns
DDI+D4T+NVP 1(5%) 0 ns
Second-line Regimen N/A
DDI+3TC+LPVr+RTV 1(4%) N/A
DDI+ABC+LPV+RTV 3(13%) N/A
ABC+3TC+LPV+RTV 3(13%) N/A
TDF+FTC+LPV+RTV 6(25%) N/A
FTC+LPV+RTV+AZT 3(13%) N/A
TDF+3TC+LPV+RTV 7(30%) N/A
TDF+3TC+LPV+RTV+AZT 3(13%) N/A
AZT+3TC+LPV+RTV 1(4%) N/A  
 
The most common NRTIs drug resistant mutations observed for the group on first-line 
therapy in this study were M184V (79%), K65R (37 %), D67N (21%), K16R (15%), 
A62V (16%), K70E/T, (5%), Y115F (5%), V75M (5%), T215Y (5%), M41L (5%) and 
K219E/Q (5%). Similar mutation patterns: M184V (71%), K65R (17 %), D67N (33%), 
K70R (29%), A62V (17%), K70E/T, (8%), Y115F (4%), V75M (13%), T215Y (13%), 
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T215F (17%), M41L (13%) and K219E/Q (8%) were observed for the group on 
second-line therapy. see Table 3.3 and figure 3.7 
The most common NNRTIs drug resistant mutation observed for the groups on first-
line therapy in this study were; K103N (40%), Y181C (30%), G190A/S (20%), V108I 
(15%), V106A/M (20%), Y181V/I (10%) and Y188C/L (10%). Drug resistance 
mutations; K103N (29%), Y181C (25%), G190A/S (29%), V108I (13%), V106A/M 
(21%), Y181V/I (4%) and Y188C/L (8%), P225H (4%) and M230L (4%) were 
observed for patients on second-line therapy.  See Table 3.3 and figure 3.8 
One or more drug RT resistance mutations were detected in 85% of patients on first-
line therapy and in 83% of patients that had been switched from first-line to second-line 
therapy, table 3.4 (a). 
The prevalence of all protease mutation observed in the study are shown in table 3.4 
(b). The most common drug resistance associated major mutations (primary active site 
mutations) reported included M46I, I54V and V82A all at 20.8% shown in figure 3.12. 
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Table 3.4 (a) frequencies of selected mutation in reverse transcriptase 
Mutations (NRTI) First-line 
regimen
Second -line 
regimen
No. (%) No. (%)
M41L 3(16) 3(13) 0.6176
A62V 7(37) 4(17) 1
K65R 4(21) 8(33.3) 0.1703
D67N 1(5) 0(0) 0.5
K70E 1(5) 2(8.3) 0.45
K70T 3(16) 7(29 1
K70R 0(0) 0(0) 0.4701
L74V 1(5) 3(13) 1
V75M 1(5) 1(4.2) 0.2425
Y115F 15(79) 17(70.8) 1
M184V 0(0) 0(0) 0.7279
L210W 0(0) 3(12.5) 1
T215Y 0(0) 4(17) 0.6176
T215F 1(5) 4(17) 0.1301
K219E 1(5) 2(8.3) 0.3626
> 1 Significant mutation (NRTI) 17(85) 18(75)
Muiltiple (≥ 2 ) drug resistance (NRTIs)
Resistance 16(80) 18(75)
intermidiate 1(5) 0(0) 1
Mutations (NNRTIS)
L100I 1(5) 0(0) 1
K101E 8(40) 7(29) 0.45
K103N 1(5) 2(8) 0.34
V106A 2(10) 3(13) 1
V106M 3(15) 3(13) 1
V108I 0(0) 1(4) 1
Y181I 2(10) 0(0) 1
Y181V 6(30) 6(25) 0.2
Y181C 1(5) 2(8) 0.7
Y188L 2(10) 0(0) 1
Y188C 4(20) 7(29) 0.2
G190A/S 0(0) 1(4) 0.72
P225H 0(0) 1(4) 1
> 1 Significant mutation (NNRTI) 17(85) 20(83.3)
Muiltiple (≥ 2 ) drug resistance (NNRTIs)
Resistance 16(80) 17(70.8)
intermidiate 1(5) 3(12.5)
P
 
NOTE. In the table above, unless otherwise stated, No. (%) was calculated from n=19 for first-line 
therapy and n=24 for second-line therapy. 
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Table 3.4 (b) frequencies of all mutations observed on the protease gene.  
First-line threapy
First -line 
threapy
No. (%) No. (%)
Mutations (PI)
L10F 0(0) 1(4.2) 1
L10V 0(0) 1(4.2) 1
L10I 0(0) 2(8.3) 1
G16E 0(0) 1(4.2) 1
K20R 1(5.2) 1(4.2) 1
M36I 17(89.4) 16(66.7) 0.1448
M46I 0(0) 5(20.8) 0.0562
I54V 0(0) 5(20.8) 0.0562
Q58E 0(0) 1(4.2) 1
D60E 1(5.2) 1(4.2) 1
I62V 2(10.3) 1(4.2) 0.5751
L63P 7(36.8) 11(45.8) 0.7563
I64M 0(0) 1(4.2) 1
H69K 17(89.4) 19(79.2) 0.437
T74S 0(0) 4(16.7) 0.1175
L76V 0(0) 3(12.5) 0.2425
V77I 0(0) 1(4.2) 1
V82L 0(0) 1(4.2) 1
V82A 0(0) 5(20.8) 0.0562
I93L 19(100) 22(91.7) 0.495
> 1 Significant mutation (NNRTI) 0(0) 5(20.8)
Muiltiple (≥ 2 ) drug resistance (PIs)
Resistance 0(0) 4(16.7)
intermidiate 0(0) 1(4.2)
P
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Figure 3.8 HIV-1 Nucleotide reverse transcriptase inhibitor (NRTI) drug resistance mutation frequencies 
in the reverse transcriptase gene of 19 subjects failing first-line therapy and 24 subjects failing second-
line therapy.  
NRTI Drug resistance 
 
Figure 3.9 shows a Stanford University HIV-1 drug resistance database translation of the NRTI drug 
resistance pattern found in first-line (n=19) and second-line therapy group (n=24). R= Resistance, I= 
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Intermediate Resistance and S= Susceptible. First-line drugs abbreviated with suffix 1st; Second-line 
drugs abbreviated with suffix (2nd). 
 
 
Figure 3.10; HIV-1 NNRTI drug resistance mutation frequencies in the reverse transcriptase gene in 19 
subjects failing first-line therapy and 24 subjects failing second-line therapy.  
NNRTI drug resistance  
 
 
Figure 3.11; shows a Stanford University HIV-1 drug resistance database translation of the NNRTI drug 
resistance pattern found between the first-line (n=19) and second-line therapy group (n=24). R= 
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Resistance, I= Intermediate Resistance and S= Susceptible. Second-line drugs were differentiated from 
first-line with the number (2) at the end of the drug abbreviation. 
 
 
Figure 3.12; HIV-1 protease inhibitor (PI) drug resistance mutation frequencies in n=19 first-line group 
and n=24 second-line group. All Kaletra drug resistance associated mutations are shown in thick bolder 
line on the bar graph. 
PI Drug resistance 
 
Figure 3.13; shows a Stanford University HIV-1 drug resistance database translation of the PI drug 
resistance pattern found in first-line group (n=19) and second-line therapy group (n=24). R= Resistance, 
I= Intermediate Resistance and S= Susceptible. First-line drugs abbreviated with suffix 1st; Second-line 
drugs abbreviated with suffix (2nd)  
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CHAPTER 4: DISCUSSION 
 
Assay validation 
The in-house genotyping assay we setup was validated in 3 phases to ensure that the 
quality of the results was not compromised before it could be adopted for routine 
clinical testing for ART patients.  
In the first phase, we compared the assay with an FDA approved ViroSeq HIV-1 
Genotyping kit. The University Teaching Hospital (UTH) in Zambia provided us with 
seven previously “Viroseq” genotyped samples for parallel testing. As is shown in the 
results section in Tables 3.1 and 3.2, the in-house assay was able to amplify and 
genotype the pol gene of all the seven samples. We compared the degree of similarly 
for each result between the laboratories using a hamming distance algorithm,[197]. The 
least comparable sample of the in-house assay sequences had 99.4% homology 
compared with the corresponding samples of the Viroseq sequence. Some studies have 
considered a hamming distance of ≥98% as acceptable,[184]. All corresponding sample 
sequences translated a 99.4% amino acid similarity. 
A phylogenetic tree of all the samples was then generated using Bioedit software as 
described in the materials and method section. The software generated the bootstrap 
trees using Kimura 2-parameter on the program DNADIST using a 
transition/transversion ratio of 1.5, which is a model for estimating evolutionary rates 
of base substitutions through comparative studies of nucleotide sequences[198]. All 
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corresponding samples had the same topology (comparing > 99%), indicative of their 
similarity.  
After establishing that the in-house assay tested as well as the Viroseq, in the second 
phase we selected five random samples and repeatedly genotyped them at three 
different time points to determine the reproducibility of the assay. The least comparable 
sample had a hamming distance of 99.5% showing the assay was able to reproduce 
tests.  All corresponding sample sequences translated a 100% amino acid similarity. 
Phylogenetic trees were generated as discussed above and all samples showed the same 
topology (> 99% similarity). 
Lastly, we participated in the National Institute of Health (NIH) Virology Quality 
Assurance (VQA) program, USA, indentify code; CIDRZ 332, for external quality 
assurance. We genotyped and submitted consensuses files of 3 five sample panels and 
our sequences showed a very high homology with other partaking sites in the panel and 
were scored acceptable (C) for each panel. This assay was adapted and modified from a 
published assay which performed similarly in the VQA program [184].    
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HIV-1 mutation pattern  
The use of combination antiretroviral therapy has drastically changed the notion that 
HIV-1 infection is a death sentence by significantly altering the disease course and 
substantially reducing the morbidity and motility rates [4-6]. The major challenge 
however as was previously mentioned is the emergence of drug resistant HIV-1 strains 
and antiretroviral agents being the major contributory cause of treatment failure [199, 
200]. A further complication is that HIV-1 drug resistance (HIVDR) mutations have 
been shown to be transmissible posing the threat of HIVDR in treatment naïve [201-
203]. 
The current cross-sectional study observed a selection of antiretroviral mutations 
(ARMs) that might result, in HIV-1, during first and second-line HAART virological 
failure. This study reported a 93% HIV-1C subtype which confirmed previous studies 
that reported it to be the most prevalent in Zambia [189]. Patients in this study had a 
wide drug combination variation during both the first-line and second-line drug 
regimen. The drug combination however followed the recommendation by the WHO 
for the use of a 2 NRTIs backbone plus one NNRTI during first-line or a 2 NRTIs 
backbone plus a PI during second-line. 
PI Resistance 
The main difference between the first-line regimen group and the second-line regimen 
group was that the NNRTIs drugs were replaced with Lopinavir/Ritonavir. We reported 
insignificant Lopinavir/Ritonavir drug related mutations in the second-line regimen 
group and completely none in the first-line regimen experienced group. This confirmed 
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the hypothesis of this study and of other similar studies that have reported insignificant 
DRM during HAART which contained Lopinavir/Ritonavir in the regimen [164-166, 
204]. Several studies of HIV-1 subtype B in patients experiencing virologic failure 
after treatment with Lopinavir/Ritonavir have infrequently detected major protease 
mutations.[164, 205]. However, HIV-1 Subtype C (95%) was most predominant in this 
study and not many studies have assessed the known drug resistance mutations in 
patients failing second-line ART or the treatment options that remains. One study by   
Wallis et al, [204] in which ninety six percent of patients in the study were infected 
with HIV-1 subtype C, the researcher reported  major protease drug resistance mutation 
following virologic failure with  Lopinavir/Ritonavir containing HAART. 
According to the latest International antiviral Society (IAS)-USA update of drug 
resistance mutation in HIV-1, the major drug resistance mutations for 
Lopinavir/Ritonavir include V32I, I47V/A, L76V and V82A/F/T/S [183, 206]. 
Genotypic data analysis of the 24 patients on second-line regimen reviewed that, only 
five patients had Lopinavir/Ritonavir drug resistance associated mutations. These 
included minor mutations M46I, I54V, L10F/I/V and major mutations L76V and 
V82A. Mutations M46I, I54V and V82A were present on all the fives sample, P=0.056 
while L76V was present in three P=0.242.  All the five samples were accompanied 
with some form of insignificantly present mutations L10F/I/V.    
The mutations M46I, I54V and V82A (P=0.0056) presented us with questions for their 
presence. Some studies have shown that these mutations commonly occur together in 
previously, PI exposed patients that are failing Lopinavir/Ritonavir containing HAART 
[206, 207]. It is possible that we observed these mutations in the five patients because 
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their previous exposures to other PIs were not indicated in their history files. It is not 
uncommon for patients in Zambia to withhold treatment information as they seek 
alternative options at different hospitals.  
According to the patient’s treatment history, patients had been second-line regimen for 
a median of 52 weeks following regimen switch from first-line regimen. As was 
described before, WHO recommended NRTI/boosted lopinavir  combination therapy 
have high genetic barrier requiring patients to be on treatment for more than 52 weeks 
before a significant selection of mutations that confer resistance [164-166]. While the 
results of patients on the first-line regimen that had virological failure (median CD4, 
149 cells/mm3 and VL 4.3 x 104 copies/mL) correlated with the drug resistance pattern 
in this study (at least 85% had developed greater the 1 drug resistance mutation), PI 
results for the second-line group did not. Less than 5% of patients on second-line 
regimen had major or minor PI resistance mutations despite all having virological 
failure (median CD4 91 cells/mm3 and VL 4.45 x 104 copies/mL).  One possible 
explanation could be that the study might have selected for patients that were not 
adhering to therapy which resulted in failure to suppress viral replication [10]. We 
designed the study to include only patients that had virological failure and excluded 
patients on a similar regimen in which treatment succeeded (VL <1000 copies/mL). 
One study recently hypothesized that patients were not adherent during second-line 
therapy due to PI drug severe toxicity [208]. 
 Another explanation could be that other mutations in the HIV genome could reduce PI 
susceptibility. Recent studies have indicated that mutations within the gag gene may 
reduce PI susceptibility. This could be another reason we observed virological failure 
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in the second-line group but insignificant PI drug resistance associated mutations. [209-
211].     
Reverse Transcriptase inhibitors drug resistance. 
During the study, a total of at least eighteen, twelve, six and four patients had a drug 
history of having taken 3TC, D4T, AZT and FTC respectively in their NRTI backbone 
during first-line therapy. Nineteen and four out of the 20 patients had at least a history 
of NVP and EFV respectively. Similarly, twenty-two, twelve, nine, six, three and two 
patients had a drug history of 3TC, AZT, D4T, TDF, FTC and ABC respectively before 
initiation of second-line therapy. There was no statistical difference between drug 
combinations in the first-line therapy group to those taken by patients in the second-
line therapy group before they were switched to second-line therapy. Therefore one 
could hypothesize that patients in second-line therapy had similar genotypic mutation 
patterns as those we observed in the first-line therapy group. This being the case, 
patients failing first-line therapy have a limited second-line drug treatment options as 
only AZT had a drug susceptibility of greater that 50% at the point first-line failure. 
NRTI drug resistance 
The most prevalent NRTIs antiretroviral mutations (ARMs) observed in this study were 
M184V (79.5%), D67N (21.1%), K65R (37%), K70R (16.7%), for the first-line therapy 
group and M184V (71%), D67N (33%), K65R (17%), and K70R (29%) for the second-
line group. The results were comparative in a similar study conducted in South Africa 
in which they reported M184V (64%), D67N (20%), and K70R (16%), as the most 
prevalent mutations after failure of first-line regimen [212]. The South African study 
however reported a significantly lower K65R mutation (2.6%) P=0.003 when 
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compared with our data. This could be attributed the fact that none of the patients had 
TDF in the drug combination which was used by at least 60.4% of patients in their drug 
combination for this study. TDF and to a lesser extent ABC have been reported to have 
a M184/K65R pathway when used in combination with 3TC or FTC [213, 214]. We 
observed a total of 25% of patients in the study that selected for the K65R mutation in 
the RT gene. 90% of these patients had a history of TDF while 9% had a history of 
ABC regime. 
The other mutation D67N, K70R, T215F/Y and T219Q are preferably selected by the 
thymidine analogue. About 79% of patients in this study had a history of either AZT or 
D4T or both.  27.9% selected for at least ≥ 1 thymidine analogue mutation (TAM). 
67% of these had a history of AZT and 25% D4T. TAMs have been reported to take 
two pathways, either TAM1 or TAM2, as was reviewed earlier. When we compared 
TAMs with one study that was carried out in South Africa by Carole Wallis at el. [190], 
we noticed a similar ARM pattern for D67N (24.5%), K70R (16.5%), T215Y (15.5%), 
K219E/Q (14.5%), L210W (7.5%) and T215F (7.5%). In the same study, M184V 
(72%) were found to be the most common NRTI ARM [190]. This study did not allow 
us to categorize these pathways as all genotypic results were carried out at one time 
point and patients had both a known and unknown drug switch history between and 
across ART classes as we had no control on their ART regimen.   
The high prevalence of the M184V mutation in our study could be explained by the 
presence of 3TC or FTC as a part of the NRTI backbone for triple therapy in all of the 
patients during first-line therapy. All groups (first and second-line therapy) in this study 
had up to 95% of 3TC incorporated in the HAART drug combination, while the first-
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line group had 21% FTC in their combination therapy and 17% for the second-line 
during first-line HAART.  Similar with Carole Wallis at el, [190] in which all patients 
had a history of 3TC in all drug regime formation during first-line therapy, our study 
observed that both groups had a prevalence of  95% 3TC and 21 % FTC.   This 
mutation has been reported to be selected during 3TC or FTC containing regimes in 
many other studies and is probably the earliest to emerge during HAART [174-176]. 
As was reviewed earlier, RT gene mutations M184V, D67N, K70R and K65N have 
been hypothesized to modify the RT enzyme at the active site in a way that results in a 
conformational change which selectively rejects thymidine analogues in the 
pyrophosphorolysis dependant mechanism [215].  
AZT had the lowest drug resistance of about 21% and 50% (Resistance plus 
intermediate resistance) for first and second-line therapy respectively. No significant 
differences were observed in the second-line therapy group between AZT and 3TC or 
the other drugs compared.  
 
NNRTI resistance 
The most prevalent mutations in the study for NNRTIs were K103N, Y181C and 
G190A/S.  Their prevalence was 40%, 30% and 20% respectively during first-line 
therapy and 29%, 30%, and 29% respectively during second-line therapy. Mutation 
YI81C is known to result in drug resistance HIV-1 viruses in all currently approved 
NNRTIs, while, mutations K103N and G190A/S are known to cause resistance to NVP 
and EFV.  These genotypic mutations are comprised of about 90% of the NNRTI major 
drug resistance mutations selected during first-line therapy in our study. These findings 
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confirm previous studies that support the limited use of NNRTIs during second-line 
therapy if they were used in first-line therapy [216, 217]. A similar study by 
Sungkanuparph  et al. more than 90% patients had drug resistance  mutations 
contributing to NNRTIs resistance following a two year cohort of a fixed-dose 
combination of stavudine, lamivudine, and nevirapine [218]. Our observations were 
also similar with another study that reported K103N (38%), Y181C (26%), and G190A 
(22%) for patients failing first-line therapy [190].  
Our study also confirmed other studies that reported a persistence of NNRTI drug 
resistance mutation during second-line ART despite the drugs not being used [204, 
208]. The mechanism by which the K103N, G190A/S and Y181C mutations in the RT 
gene result in NNRTI inhibition though not certain, have been hypothesized. K103N is 
suggested to result in NNRTI resistance by blocking drug entry into the RT binding 
pocket. Studies that have compared the structures of unligated wild type RT with the 
K103N mutant RT have shown that the mutant structure has hydrogen bonds that are 
not present in the wild-type; these  lead to a conformational change that resembles a 
closed structural form of the HIV-1 wild-type RT binding pocket [219]. This mutation 
is known to reduce the susceptibility of EFV and NVP by ~20-fold and ~50-fold 
respectively but still remains fully susceptible to the second generation NNRTIs, 
etravirine and Rilpivirin [220, 221]. 
HIV-1 RT gene mutation Y181C and  Y188C in contrast to K103N have been 
hypothesized to result in drug resistance by causing the loss of an aromatic ring with 
the inhibitor binding pocket, which is needed for most first generation inhibitors such 
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as NVP  and EFV [222]. This mutation is known to cause drug resistance in all current 
FDA approved NNRTIs.  
Lastly, mutations of glycine to glutamic acid or glutamine at position 190 of the HIV-1 
RT has been hypothesized to create a steric bulk within the NNRTI binding site via 
extensive van der waal interaction residues, leading to a conformational change within 
the pocket preventing inhibitor binding [223].  The mutation does not cause a reduction 
in second-generation NNRTIs (ETR and Rilpivirin) susceptibility [183]. 
Figure 4.2 below shows a Stanford University HIV-1 drug resistance translation of the 
mutation pattern found between the first and second-line therapy group. AZT had the 
lowest drug resistance of about 21% and 50% (Resistance plus intermediate resistance) 
for first and second-line therapy respectively.  
 
Conclusion 
This study demonstrated that the previously published affordable “in-house” 
genotyping assay, effective for genotyping non-subtype B HIV-1[184], could be used 
as an alternative to the more expensive commercial for kits in Zambia. The assay costs 
a third of the cost of commercial kits and was designed to effectively genotype HIV-1C 
which predominate the Zambian population. 
The study also gives insight into the selection of the Reverse transcriptase and Protease 
gene mutations by NRTI/NNRTI or NRTI/PI during routine care in Zambia. Major PI 
mutations were insignificant in patients exclusively treated with Lopinavir/Ritonavir as 
the only PI during second-line HAART. The use of most of the FDA approved PI 
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would therefore be good for subsequent treatment. While RT mutations correlated with 
virological results and could easily be used to predict treatment failure, PI mutations 
surprisingly did not correlate with patient virological failure seen in study population. 
Either other genes that could reduce PI susceptibility such as gag are responsible for 
drug failure, or patient are not adhering to medication during second-line therapy as a 
result of enhanced drug toxicity. Including the gag gene as a part of PI drug resistance 
testing in addition to genotyping the Protease gene could provide additional 
information about PI resistance. It is possible that the Lopinavir/Ritonavir genetic 
barrier is lower than most clinical trials have reported considering that most trials 
excluded gag during genotyping. But again, poor drug adherence could be the cause for 
the virological failure in this study population. 
Lastly, the study reviews that patients have a limited NRTI back bone for use during 
either second line or third line therapy.  We recommend a drug resistance testing to 
determine NRTIs to be used subsequent to first-line ART failure in Zambia.   AZT, 
D4T and TDF respectively remain the most effect NRTIs while 3TC and FTC the least 
effective. 
Alternatively, boosted PIs could be used in combination with integrase inhibitors such 
as Raltegravir where a drug resistance testing is not available although comparative 
data will be needed. 
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APPENDIX A: 
 
Procedure for Qiagen Viral RNA mini kit isolation and purification for In-House 
Genotyping 
VI. PURPOSE/PRINCIPLE:   To isolate and purify HIV RNA from Plasma (treated 
with anticoagulants other than heparin) using the Qiagen Viral RNA mini kit. 
Samples may be fresh or frozen, but if frozen, should not be thawed more than once 
 
A. Materials 
EQUIPMENT: Bench top micro-centrifuge Pipettes (1-10 µl, 10-100 µl, 100-1000 µl), 
vortex mixer, -20˚C freezer, refrigerator, timer, tube racks. 
 
REAGENTS:  
Carrier RNA 
WB1 buffer 
WB2 buffer 
AVE and AVL 
 
MATERIALS: 
Matrix tips 
Micro centrifuge tubes, 1.5ml 
Pipettes  
Gloves 
Centrifuge  
 
II. SPECIMEN TYPE / STORAGE 
 
Type: Plasma treated with anticoagulants other than heparin 
 
Handling Conditions:  
 Sample should be separated from plasma within 2 hours of collection. 
 Spin sample at 1000rpm for 15 minute and aliquot into clean RNase free 1.5ml 
tube  
 
Storage: 
 Store sample at -70oC 
  
PROCEDURE:  (Time required:  three hours) 
NOTE: Standard (unplugged, non-sterile) pipette tips may be used for this procedure. 
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Check expiration date of kit and record on Nucleic acid Extraction Record Sheet.  
 
Step Sample concentration. 
1 Record the samples you intend to extract on the Nucleic acid extraction sheet. 
Include one sample from the previous run that got sequenced as positive 
control and RNase free deionized water for negative control 
2 Put orientation marks on the1.5ml  microfuge tube. Mind not to mark the lid 
tops as these can change position during spin. 
3 Add 500ul of sample in each tube and RNase free water in the Negative 
control 
4 Put the tube in the centrifuge with orientation marks facing upwards. 
  5 Spin in a refrigerated centrifuge at 20,000-22000 x g for one hour at 4oC 
  6 After centrifugation stops, quickly pipette out 360ul of plasma. This should be 
done from the position opposite to the orientation marks. Ensure that you do it 
gently but within two minutes for all samples. Do not run more than 10 
samples at the time. If you take longer than 5minutes, repeat the spinning step 
5 
  7 Vortex the remaining 140ul and add 5.6ul of carrier RNA in each tube. 
  8 Quick spin for 2-4 seconds. 
 
9 Add 560ul of AVL in each tube. 
 
10 Vortex and quick spin 
11 Incubate at room temperature (15–25°C) for 10 min. 
12 Add 560 μl of ethanol (96–100%) to the sample, and mix by pulse-vortexing 
for 
15 s. After mixing, briefly centrifuge the tube to remove drops from inside the 
lid. 
 Wash and Dry. 
13 Carefully apply 630 μl of the solution from step 5 to the QIAamp Mini column 
(in a 2 ml collection tube) without wetting the rim. Close the cap, and 
centrifuge at 6000 x g (8000 rpm) for 1 min. Place the QIAamp Mini column 
into a clean 2 ml collection tube, and discard the tube containing the filtrate 
14 Carefully open the QIAamp Mini column, and repeat step 13. 
15 Carefully open the QIAamp Mini column, and add 500μl of Buffer AW1. 
Close the cap, and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the 
QIAamp Mini column in a clean 2 ml collection tube (provided), and discard 
the tube containing the filtrate. 
16 Carefully open the QIAamp Mini column, and add 500μl of Buffer AW2. 
Close the cap and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min. 
Continue directly with step 18, or to eliminate any chance of possible Buffer 
AW2 carryover, perform step 10, and then continue with step 18 
17 Recommended: Place the QIAamp Mini column in a new 2 ml collection tube 
(not provided), and discard the old collection tube with the filtrate. Centrifuge 
at full speed for 1 min. 
 Elution: 
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18 Place the QIAamp Mini column in a clean 1.5 ml microcentrifuge tube (not 
provided). Discard the old collection tube containing the filtrate. Carefully 
open the QIAamp Mini column and add 60 μl of Buffer AVE equilibrated to 
room temperature. Close the cap, and incubate at room temperature for 1 min. 
Centrifuge at 6000 x g (8000 rpm) for 1 min. Store at -20o C for short term > 
21day of at -70o C for > 21 day. 
 
 
APPENDIX B: 
 
Procedure for Reverse Transcription (RT) of RNA for In-house genotyping 
 
PURPOSE/PRINCIPLE:   To generate cDNA from RNA using the in-house method 
HIV-1 cDNA is generated as a template for PCR amplification.  HIV-1 RNA is copied 
into cDNA using the enzyme; expand reverse transcriptase and a specific reverse 
primer.  
VII. MATERIALS AND EQUIPMENT:  
 
A. Materials/Equipment 
 
Thermo-cycler 
UV light enclosure (Dead 
Air Box, reagent and 
sample) 
Timer 
Area dedicated pipettes 
-20° C freezer 
Refrigerator 
Vortex mixer 
MicroAmp Tray/Retainer 
set 
MicroAMP Caps 
Biosafety hood 
Centrifuge 
Ice tray 
Waste tray 
 
Microcentrifuge tubes 1.5 ml 
MicroAmp Reaction tubes 0.2 ml 
Matrix sterile, plugged-filter tips 
 
B. Reagent   
5x Reverse Transcriptase 
Buffer 
DTT (100mM) 
dNTP (10mM) 
RNAse Inhibitor  
Expand Reverse 
Transcriptase Enzyme 
Reverse Primer (CWR1 
u) 
 
C. Specimen 
HIV-1 RNA extracts prepared 
according to the protocol: RNA 
Extraction (appendix A). 
 
 
 
Handling Conditions:  
 HIV-1 RNA is considered to be infectious. Wear a laboratory coat and gloves 
whenever handling RNA extracts. These gloves and gowns are not to be 
removed from the clean room. 
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 Vials containing RNA extracts should be opened only inside the Dead Air Box 
in the sample room and never on an open bench. 
 Immediately change gloves if visibly contaminated with liquid or damaged. 
 Details on waste disposal and decontamination of equipment are provided in the 
protocol: RNA Extraction. 
 
B. Equipment 
 
Centrifuge, sample 
 
III. STORAGE REQUIREMENTS 
 
 Components of the in-house Genotyping method are stored in the –200C freezer 
in the reagent room. Record the date received and date opened on the reagent 
lists.  
 
A. Rejection Criteria 
 
1. Do not use haemolysed, contaminated or lipaemic serum or plasma.  
2. Hemolyzed samples are unacceptable when the level of hemolysis reaches 
the point when “printed matter cannot be read through it” 
 
 
IV. QUALITY CONTROL: 
 
Successful reverse transcription is indicated by amplification of sufficient PCR product 
for sequencing. A negative control (RNase free deionized water) and positive control 
are included with each batch of reverse transcription reactions. When results from the 
subsequent PCR amplification are analyzed (see Agarose Gel Electrophoresis), the 
negative control detects contamination of reactions with HIV-1 DNA from previous 
reactions. The positive control indicates that the procedure and reagents for reverse 
transcription are working properly. Do not process any samples from a run whose 
negative control indicates amplification after gel electrophoresis.  
 
 
V. PROCEDURE:  
 
IMPORTANT: Use only sterile, plugged pipette tips for this procedure! 
 
 
 
In Sample Dead Air box: 
 
 
 
Step Action 
1 Place RNA extracts in the Dead Air Box and thaw at room temperature.  
2 Place the Positive Control RNA Extract and Negative RNA Control Extract 
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in the Dead Air box in the sample room  
 
In the dead air box in the reagent room: 
 
Step Action 
3 Label a 200ul MicroAmp reaction tube for: each sample, negative control, 
positive control.  Label tubes with the 1- or 2-digit numbers indicated on the 
RT/PCR in-house Record Sheet. 
4 Thaw the 5xRT buffer, 100mM DTT, 10mM dNTP and 20u CWR1 
5 Add 2.5ul of the reverse primer CWR1 into each microamp tube 
6 Transfer to the dead air box in the sample room 
 
In Sample Dead Air box: 
 
Step Action 
7 Place MicroAmp tubes into the retaining rack. 
8 Open the MicroAmp tubes.  Carefully pipette 8ul of RNA extract to the 
bottom of the corresponding tube and mix the sample and primer and cap 
the tubes,.  
9 Add 8 ul of the Positive RNA Control Extract to the Positive Control 
tube. This should be the next to last tube. 
10 Add 8 ul of the Negative RNA Control Extract to the Negative Control 
tube.  This should be the last tube. 
11 Check that the volume in each tube is similar by lifting the retaining rack 
and inspecting the tubes.  Each tube should contain 10.5 ul. 
12 Place the microAmp tubesonto the thermocycler  
13 Select the cycle sequencing program: 
USER: TMP 
Method: In-house RT 
Select “View” and review method for correctness: 
14 Temperature (oC) Time 
 65 10 min 
 42 60 min 
 4 ∞ 
15 Select “Start” 
16 Confirm reaction volume is 20 ul, select “Start”  
The program will start. 
Note: You will pre-incubate the primers and sample at 65 oC for 10 minute. 
The moment the temperature drops to 42, pulse the  
 
In the dead air box in the reagent room-during the 10 minutes make up the following 
RT master mix: 
 
Step Action 
17 In a 1.5 ml microcentrifuge tube, add the following reagents in order 
(prepare enough for n samples) : 
 Reagent Volume for n=1 rxn (ul) 
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 5x RT Buffer 4 
 DTT 2 
 dNTP (10mM) 2 
 RNAse Inhibitor  0.5 
 Expand RT 1 
 Final volume 9.5 
18 Add the RNAse Inhibitor directly into the RT mix.  Pipette up and down 3 
times to rinse the pipette tip. 
19 Add the Expand RT enzyme directly into the brewmix.   Pipette up and 
down 3 times to rinse the pipette tip. 
20 IMPORTANT: Vortex the RT brewmix 3-5 seconds (low speed).  
21 Return the RT reagents to the freezer. 
22 Centrifuge the RT brewmix briefly in the microfuge to bring the contents to 
the bottom of the tube. 
23 Place the RT brewmix into the Eppendorf cold block located in the -20oC 
freezer in the sample prep area 
24 Once the 10 minutes is up, let temperature drop to 42oC and PAUSE the 
thermocycler 
NOT
E 
When you press PAUSE, the thermal cycler will resume the method after 
10 min. You have these 10 minutes to perform the following steps. 
25 Remove the microAmp tubes and place on the Eppendorf Cold Block 
26 Add 9.5ul of brew mix to each microamp tube 
27 Put the samples back into the Thermal Cycler. 
28 Press RESUME to continue at 42oC for 60min. 
29 When finished, hold samples at 40C for at least 10 minutes or store at  
–200C until PCR is performed. 
 
 
Store the cDNA samples: 
 
If you plan to..... Then..... 
Set-up PCR products within 1 hour Leave the samples at 4oC on the thermocycler. 
Set-up PCR at a later date Store the cDNA samples in the –20oC freezer in 
the sample area. 
 
 
APPENDIX C 
 
Procedure for amplifying cDNA for In-house genotyping 
 
I. PURPOSE/PRINCIPLE:   :  To amplify cDNA The polymerase chain reaction 
(PCR) is used to amplify a 1.6 kb cDNA from HIV-1 cDNA generated using the 
protocol: In-house Reverse Transcription (RT) Protocol.  The amplified cDNA 
includes coding sequences for HIV-1 protease (the entire protein, amino acids 1-99) 
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and HIV-1 reverse transcriptase (amino acids 1-324).  This cDNA can be 
sequenced to identify drug resistance mutations in these HIV-1 proteins 
 
Note: This procedure is performed in the clean room. Review HIV GENOTYPING LAB 
PROCEDURAL GUIDELINES before using the clean room. 
 
 
 
II. MATERIALS AND EQUIPMENT:  
 
EQUIPMENT:   
Thermal cycler 
UV light enclosure (Dead Air Box, reagent and 
sample) 
Timer 
Area dedicated pipettes 
-20˚C freezer 
Refrigerator 
Vortex mixer 
MicroAmp Tray/Retainer-set 
MicroAmp Caps 
Biosafety hood 
Microfuge 
Ice tray 
Waste carton 
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REAGENTS:   
5xBuffer 
dNTP 
CWR-1( 5’GCATACTTYCCTGTTTTCAG 3’) 
CWF-1 (5’GAAGGACACCAAATGAAAGAYTG 
3’) 
Expand reverse transcriptase (Roche) Enzyme 
Distilled Water 
 
MATERIALS: 
Matrix sterile, plugged-filter tips 
MicroAmp Reaction tubes 0.2 ml 
Micro centrifuge tubes, 1.5 ml 
 
 
VI. SPECIMEN TYPE / STORAGE 
 
Type: HIV-1 cDNA prepared according to the protocol: In-house Reverse 
Transcription  
 
Handling Conditions:  
 HIV-1 cDNA is considered to be potentially infectious.  
 Wear a laboratory coat and gloves whenever 
handling samples in this protocol. These 
gloves and gowns are not to be removed from 
the clean room. 
 Vials containing cDNA should be opened only inside the Dead air box in the 
sample room and never on an open bench. 
 Immediately change gloves if visibly contaminated with liquid or damaged. 
Details on waste disposal and decontamination of equipment are provided in the 
protocol: RNA Extraction 
 
Storage: 
 Reagents of the PCR are stored in the –200C freezer in the reagent room. 
  A 50 ml bottle of nuclease-free water is stored at room temperature in the resistance 
cabinet 
 
 
VII. PROCEDURE:   
 
IMPORTANT: Use only sterile, plugged pipette tips for this procedure. 
 
 
In the Dead air box in the reagent room: 
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Prepare the PCR brewmix:  To avoid having to pipette small volumes, prepare 
enough PCR brewmix for at least 5 reactions. 
 
Step Action 
1 Thaw the PCR buffer, dNTP, Primers: CWR-1 and CWF-1 in the dead air box 
2 Determine the volume of PCR brewmix needed as follows: 
For n samples-This will include enough for the samples, the positive and 
negative control reactions this includes an amount for pipetting error. 
4 In a 1.5 ml microcentrifuge tube, add the following in order: 
 Reagent Volume for 1 sample 
 5x Buffer 10ul 
 dNTP 1ul 
 CWR-1 1ul 
 CWF-1 1ul 
 Enzyme 0.5ul 
 Water 33.5ul 
 Total 47.5ul 
Note Pipetting in the following steps is critical.  Follow the protocol exactly as 
written. 
5 Add the enzyme directly into the PCR mix.  Pipette up and down 3 times to rinse 
the entire enzyme from the pipette tip. 
6 Vortex the PCR brew mix 3-5 seconds to mix (low speed). 
7 Centrifuge the PCR brew mix briefly in the microfuge to bring the contents to 
the bottom of the tube. 
8 Return the PCR reagents to the freezer. 
9 Place the PCR brew mix in the Dead air box in the sample room.   
IMPORTANT:  Proceed immediately to the next step.  Do not store the PCR 
brewmix (see below). 
 
In Dead air box in the sample room: 
 
Step Action 
1 Remove the RT reactions from the thermalcycler and place them in the 
MicroAmp tray in Dead Air Box. 
Abort the RT-program on the thermal cycler. 
Note Pipetting in the following steps is critical.  Follow the protocol exactly as 
written. 
2 Carefully pipette 30ul of the PCR brewmix directly into the sample.  Pipette up 
and down 2-3 times to mix, then cap the tube. 
3 Repeat step 2 for each tube.  Use a separate pipette tip for each sample.  
4 Check that the volume in each tube is similar by lifting the retaining rack and 
inspecting the tubes.  Each tube should contain 50ul. 
5 If there are any drops on the side of the tubes, spin the reactions tubes for 5-10 
seconds. 
6 Discard unused PCR brewmix. Proceed immediately to the next step.   
Stellenbosch University  http://scholar.sun.ac.za
 115 
 
 
 
Perform the PCR reaction:  
The PCR reaction is performed in the in thermo-cyclers the post PCR room.    
 
 
 
Complete the run:  
The PCR reaction should take about 4.5 hours. When the program is complete: 
 
Step Action 
1 Remove the 0.2ul tubes from the thermocycler.  
Turn off the thermalcycler. 
2 Place the retaining rack in 2% bleach in the dirty lab.   
 
Store the PCR samples: 
 
If you plan to..... Then..... 
Purify the PCR products within 1 
hour 
PCR samples may be left in the thermocycler 
for 1 hour. 
Purify the PCR products at a later 
date 
Store the PCR samples in the Sequencing Lab 
in the freezer inside the box labeled 
“Unpurified PCR products”. 
 
Step Action 
1 Place the MicroAmp tubes into the block of the thermal cycler.  
2 Program the thermocycler to the conditions as shown below. 
 
3 
 
Number of 
cycles 
Temperature 
(oC)
Time Extra 
- 94 2 min  
10 94 30 seconds  
54.5 30 seconds  
72 2 min  
35 94 30 seconds  
55 30 seconds  
72 2 min* * Increase of 10 
seconds with 
every cycle 
- 72 10 min  
- 4 ∞  
4 Select “Start” 
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APPENDIX D: 
 
Procedure for GFX Micro-Spin purification of PCR products for In-House 
Genotyping 
 
 
 
I. PURPOSE/PRINCIPLE:   To purify PCR products, by removing primers and 
buffer .Primers and buffers are removed from PCR products using a quick-spin 
column to purify PCR products for gel analysis and sequencing  
 
B. Materials 
EQUIPMENT: Bench top micro-centrifuge Pipettes (1-10 µl, 10-100 µl, 100-1000 µl), 
vortex mixer, -20˚C freezer, refrigerator, timer, tube racks. 
 
REAGENTS:  
RNase/Dnase free deionized  water 
Illustra GFX PCR DNA purification 
Band Purification kit. 
 
MATERIALS: 
Matrix tips 
Microcentrifuge tubes, 1.5ml 
Pipettes  
Gloves 
 
VIII. SPECIMEN TYPE / STORAGE 
 
Type: PCR products prepared according to the procedure for amplifying cDNA as has 
been described in, Procedure for amplifying cDNA in-house genotyping, Appendix C 
 
Handling Conditions:  
 PCR products are unlikely to be infectious. However, you should wear gloves 
whenever handling samples in this protocol.  
 This procedure may be performed on an open bench. 
 Immediately change gloves if visibly contaminated with liquid or damaged. 
 All waste should be disposed of in double bagged biohazard waste bins. When 
the bin is three quarters full, the bag should be twisted closed, sealed with 
autoclave tape and taken to the autoclave room for autoclaving.   
 
 
Storage: 
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 A 1.5 ml microfuge tube of Rnase free water is stored on the bench/fridge in the 
Post-PCR Lab. 
 Illustra GFX PCR DNA purification Band Purification kits are stored in a 
cabinet in the Post-PCR Lab. 
 
 
IX. PROCEDURE:  (Time required:  twenty minutes per test or batch of tests) 
 
NOTE: Standard (unplugged, non-sterile) pipette tips may be used for this procedure. 
Check expiration date of microcons and record on Agarose Gel Record Sheet.  
 
Purify the PCR Products: 
Step Sample capture: 
  1 Label 2 sets of 1.5 ml Microcon collection vials for each sample. 
The vials used for final collection should contain the PID#, sample date and 
date of purification. 
  2 Assemble the GXF MicroSpin concentrator as described in the package insert. 
  3 Pipette 500 ul of capture buffer type2 into ≤100ul of sample. If sample volume 
is greater than 100ul divide the sample and purify using more than one GFX 
Micro-Spin column. Mix thoroughly  
  4 Note: if sample contains DNA greater than 5kbp. Do not vortex, as this may 
cause shearing of the DNA. 
 
For each purification that is to be performed, place on GFX, Micro-Spin 
column into one collection tube. 
 
 Sample Binding: 
1 Centrifuge Capture buffer type 2-sample mix briefly to collect the liquid at the 
bottom of the GFX Micro-Spin column and collection tube. 
 
2 Load the Capture buffer type 2-sample into the assembled GFX Micro-Spin 
columns and collection tube. 
3 Spin the assembled column and the collection tube at 16 000 x g for 30 
seconds 
 
4 Discard the flow through by emptying the collection tube. Place the GFX 
Micro-Spin column back inside the collection tube 
 
 Wash and Dry. 
1 Add 500 ml wash buffer type 1 to the GFX Micro-Spin column. 
2 Spin the assembled column and collection tube at 16 000 x g for 30 sec 
 
Note: Wash and Dry steps 1 and 2 can be repeated when purity is paramount, 
for example if the sample is to be used in a blunt-ended ligation. This extra 
wash step may reduce yield by 4% 
 
3 Discard the Collection tube and transfer the GFX MicroSpin column into a 
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fresh Dnase-free 1.5ml micro centrifuge tube ( not supplied in the kit) 
 
 Elution: 
1 Add 40ul elution buffer type 6. If the band on electrophoresis gel were weakly 
bright, as 20ul of elution buffer 6 to the centre of the membrane in the 
assembled GFX Micro-Spin column and sample Collection tube. 
2 Incubate the assembled GFX Micro-Spin column and sample Collection tube 
at room temperature for 1 minute. 
3 Spin the assembled column and sample Collection tube at 16 000 x g for 1 
minute to recover the purified DNA. 
4 Proceed to downstream application. Store the purified DNA at -20oC 
 
Store the Purified PCR products: 
If you plan to..... Then..... 
Analyze the PCR products on an agarose gel 
or nanodrop within 1 hour 
PCR samples may be left on ice for 1 
hour or may be put in the refrigerator. 
Analyze the PCR products at a later date Store the PCR products in the –200C 
freezer in a box labeled “Purified 
undiluted PCR Products”. 
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APPENDIX E 
 
Procedure for quantification of PCR products for genotyping using the in-house 
method. 
 
I. PURPOSE/PRINCIPLE:   
To purify amplified products, so that they can be quantified and diluted for cycle 
sequencing. DNA fragments are separated by electrophoresis in agarose gels. DNA 
bands within the gel are detected by staining with the fluorescent intercalating dye, 
ethidium bromide, and visualizing with a UV light source.  DNA fragments are 
identified by comparison to fragments from DNA size markers 
 
II. MATERIALS AND EQUIPMENT:  
 
EQUIPMENT: bench-top micro-centrifuge, Pipettes (1-10 µl, 10-100 µl, 100-1000 µl), 
vortex mixer, -20˚C freezer, refrigerator, timer, tube, Electrophoresis equipment, 
waste system for ethidium bromide disposal, 1 liter graduated cylinder, 
 
REAGENTS:  
Sterile, deionized RNase free water 
MassRuler DNA Ladder 
Gel Loading Solution 
Agarose 
1 X TAE/TBE buffer 
Deionized water 
 
MATERIALS: 
Matrix tips 
0.2ml strip tubes 
gel loading tips  
Kimwipes 
Activated Charcoal 
 
 
III. SPECIMEN TYPE / STORAGE 
 
Type: PCR products purified according to the protocol: As stated in the Illustra GFX 
kit (Appendix D) 
 
Handling Conditions:  
 You should wear gloves whenever handling samples in this protocol.  
 Ethidium bromide is a carcinogen. It is incorporated into the agarose gels, and 
also leaches into the buffer chambers during electrophoresis. You must always 
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wear gloves when handling the gels, gel boxes and also when disposing of 
buffers. Used buffer should be poured into the bottle labeled “Dirty Ethidium 
Bromide” once the bottle is full the bottle undergoes appropriate disposable ( 
according to national guidelines) 
 Gels are photographed using a cannon digital camera.  
 Immediately change gloves if visibly contaminated with liquid or damaged. 
 All waste (except for gel buffers) should be emptied into the biohazard bin 
when finished with this procedure. 
Use of electrophoresis equipment 
 The electrophoresis gel box is equipped with a safety lid. Do not turn the power 
supply on until the gel box is prepared, the lid is closed, and the electrodes are 
plugged in.   
 Do not open the gel box lid, touch the gel or gel buffer, or unplug the electrodes 
while the power supply is on. At the end of a run, turn off the power supply 
first, and then unplug the electrodes.  
 You may then open the box and remove the gel.  
 
DNA Mass Ladder and Gel Loading Solution 
 The DNA mass ladder and gel loading solution are stored at -20oC in the freezer 
room while the working dye is stored at 2oC to 8oC fridge in the post PCR 
room. 
 
 
 
IV. PROCEDURE:    
 
 A Quantification of DNA using gel electrophoresis 
 
NOTE: Standard (unplugged, non-sterile) pipette tips may be used for this procedure. 
Before beginning, check the lot numbers of the gels, loading buffer and DNA mass 
ladder and record on the Agarose Gel Record Sheet. 
 
Prepare 0.ug/ml ethidium bromide 0.8% gel 
 
Prepare the Samples: 
Step Action 
1 Enter sample information onto the Agarose Gel Record Sheet. 
2 Place the DNA mass ladder and Gel Loading Solution on the bench. 
3 Thaw the purified DNA samples, if necessary. 
4 Label a 0.2 ml strip tubes for each sample including positive and negative 
controls. 
5 Add 1 ul of 6x gel Loading Solution to each tube. You may use a single pipette 
tip for this. 
6 Add 5 ul of each purified DNA sample to the appropriate tube.  Pipette up and 
down three times to mix.  Use a separate pipette tip for each sample. 
7 If needed, micro centrifuge tubes at low speed for 5-10 seconds to collect any 
drops formed on the sides of the tubes. 
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Load the Gel: Load samples slowly using the designated gel area pipette.  The 
quantity is critical, if it is used as a reference to determine dilutions prior to sequencing. 
Carefully place the pipette tip in the well of the gel without piercing the gel bottom.  
The samples will sink slowly to the bottom of the well.  Be careful not to agitate the gel 
while loading.  
 
Run the gel: 
IMPORTANT: Agarose gels contain ethidium bromide which is a mutagen.  The 
ethidium bromide leaches into the running buffer during the gel run.  Wear gloves for 
the following procedures. See other handling precautions above.  
 
Step Action 
1 Place the cover on the gel apparatus. 
2 Connect the color coded electrodes to the red and black ports on the power 
supply. 
3 Turn on the power supply.  It should be set for constant voltage. 
4 Adjust voltage to 75-80 volts (10 volts/cm of gel). 
5 Run the gel for about 45-60 minutes.  The bromophenol blue dye should 
migrate approximately 2 cm from the wells.  
6 Turn off the power supply. 
7  Disconnect the electrodes. 
8 Place on the transilluminator and turn on 
9 Photograph the gel with the Polaroid camera. 
10 Turn off the transilluminator 
11 Dispose of the gel in a biohazard waste box.
12 Pour off the running buffer (which contains ethidium bromide) into the funnel 
of the Dirty Ethidium Bromide Bottle and let the liquid drain (when the buffer 
becomes cloudy). 
 
Step Action 
1 Vortex the DNA Mass Ladder gently before use 
2 Pipette 10 ul of the DNA Mass Ladder onto the first gel lane.  
 Note:If you run a gel with two combs, load both DNA Mass Ladder samples 
onto the first lanes for each comb 
3 Load samples onto the gel, in order listed on the Agarose Gel Record Sheet. 
4 Place the samples in the refrigerator while the gel is running so they can be 
diluted after the gel run (see below). 
5 Return reagents to the freezer. 
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A Quantification of DNA using Nanodrop  
 
  The Sample Retention System 
A B  
Step Action 
1  
With the sampling arm open, pipette 1.5 to 2 ul deionized RNase 
free water onto the lower measurement pedestal (A) and (B) 
 
2  
Close the sampling arm and initiate a spectral measurement 
using the operating software on the PC. The sample column is 
automatically drawn between the upper and lower measurement 
pedestals and the spectral measurement made  (C) 
  
   
NOTE: PC operation software will guide you on to blank if you are starting up 
the instrument for the first time. For more information, consult the NanoDrop 
user’s manual V3.7 full installed on the operation software. 
 
3 Load the blanking solution (deionized RNase free water) and take the reading. 
Label it as blank 
4  
 
When the measurement is complete, open the sampling arm and wipe the 
sample from both the upper and lower pedestals using a soft laboratory wipe 
(kimwipes). Simple wiping prevents sample carryover in successive 
measurements (D) 
5 Repeat the step 1-4 for samples. Remember to label for each sample. 
6 Once sample testing is complete, clean the nanodrop as stated in the nanodrop 
SOP and unplug the instrument. 
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C  D  
 
 
Calculations 
 
The NanoDrop software automatically calculates the absorbance for nucleic acid in 
ng/ul 
 
If sample concentration is less than 6 ng/ul run a second PCR on the samples. 
If concentration is between 6-14 ng/ul, use the neat concentration for sequencing 
If concentration is above 14, dilute samples to 10-14 ng/ul for cycle sequencing 
purposes. 
 APPENDIX F 
 
Procedure for Cycle Sequencing and purifying using in-house genotyping 
methodology 
 
I. PURPOSE/PRINCIPLE: Dideoxy (chain termination) sequencing is performed 
using the Big Dye Terminator Kit (Version 3.1) and 5 primers. Standard sequencing 
includes 2 primers for the sense strand of the PCR products (P41, P42), and 3 
primers for the anti-sense strand of the PCR products (P43, P44, P45).  Together, 
these primers provide complete bidirectional sequencing information for the region 
encoding HIV-1 protease and HIV-1 reverse transcriptase to amino acid 300.   
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II. MATERIALS AND EQUIPMENT:  
 
 
 
Absolute Ethanol and Sodium Acetate. 
HiDi Formamide 25ml bottle-Aliquotted into 1.5ml 
Eppendorf tubes 
RNAse free deionized water 
Big Dye Terminator Kit version 3.1 
 
Primary Primers 
 
Primer 21 (5’ GGA GGT TTT ATC AAA GTA AGA 
CAG TAT GA 3’) 
Primer 41 (5’ CCTCAAATCACTCTTTGGC 3’) 
Primer 42 (5’ AGAACTCAAGACTTTTGGG 3’) 
Primer 43 (5’ TGCTGGGTGTGGTATTC 3’) 
Primer 44 (5’ TCCCTGTTCTCTGCCAATTC 3’) 
Primer 45 (5’ TGGTAAATTTGATATGTCCATTG 
3’) 
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III. SPECIMEN TYPE / STORAGE 
 
B. Specimen Type and Storage 
 
 Type: Purified PCR products diluted according to the “Procedure for 
quantification of PCR products for genotyping using the in-house 
method” and “Procedure for GFX MicroSpin purification of PCR 
products for genotyping using the in-house method” SOPs  
 Ethanol, stock solution of 3M sodium acetate and deionized RNAse free 
water are stored in the clean room. Remove one bottle of each for use in 
the Sequencing lab.  When they are empty, get a new bottle from the 
clean room. 
 The Big Dye Terminator Kit and Primers are stored in the –20oC freezer 
in the clean room. 
 The Big Dye Terminator buffer is stored in the 4oC fridge in the clean 
room. 
 
C. Handing conditions 
1) This protocol is performed on the bench in the Sequencing Lab.  
2) It is not necessary to use plugged pipette tips for this procedure. 
3) Wear gloves whenever handling samples in this protocol.  
4) Change gloves if visibly contaminated with liquid or damaged. 
5) All waste should be disposed of in Biohazard Waste boxes lined 
with biohazard waste bags 
 
 
IV. PROCEDURE:   
 
 
A. Preparing the Sequencing Reactions: 
 
Step Action 
1 Thaw Diluted, purified PCR products, Big Dye terminator Mix and 
Primers 41, 42, 43, 44, and 45.  Take out the Big Dye Terminator 
Buffer from the fridge 
2 Pulse vortex the Big Dye terminator Mix, Primers and Big Dye 
Terminator Buffer 
3 Make up a Mastermix into a 1.5ml RNAse free microfuge tube using 
each different primer for the number of samples processed: 
 
Reagent Volume for 1 Sample 
Big Dye terminator Mix 4ul 
Primer (3.2pmol; 41 or 42 or 43or 
44 or 45) 
1ul 
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Big Dye Terminator Buffer 2ul 
Water 2ul 
 
For each pipetting step, lift the plate and directly observe the 
MasterMix being dispensed into the bottom of the well.  Refer to the 
Sequencing Record Sheet to determine which HIV Seq Mix goes in 
which well and mix with the PCR product.  Use a separate pipette tip 
for each Master Mix. 
 
4 Add 1 ul of sample DNA to appropriate well. Make sure you add 
according to the way you arranged them in the sequencing record sheet. 
Change tips between samples. 
5 Cover the plate with a rubber full-plate cover or plastic cover seals 
Note: Place the A1 position on the cover on the top left corner of the 
plate 
6 Check that the volume in each well is similar by lifting the plate and 
inspecting the well.  Each well should contain 20ul. 
7 If any drops are on the sides of the wells, spin the plate, ensure the 
centrifuge is balanced. Allow the speed to come to approx. 600 rpm 
(approx. 30 seconds), then stop the spin. 
8 Record the lot # of reagents on the Sequencing Record Sheet. 
 
Incubating the Sequencing Reactions in the Thermalcycler:    
Step Action 
1 Turn on the ABI 9700 thermalcycler. 
2 Place the retaining rack with the samples in the thermalcycler and close 
the lid. 
3 Select the cycle sequencing program: 
USER: TMP 
Method: Cycle Seq in-house  
Review the program for correctness. 
Select “View” and review method for correctness: 
 Number of cycles Temperature (oC) Time 
 1 96 1min 
 25 96 10sec 
 55 5 sec 
 60 4 min 
 - 4 ∞ 
4 Select “Start” 
5 Confirm reaction volume is 20 ul, select “Start”  
The program will start. 
 
Complete the run:   
The PCR reaction should take about 2.5 hours.  When the program is complete: 
Step Action 
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1 Remove the sequencing plate from the thermalcycler and transfer it to 
the bench.   
2 Turn off the thermalcycler.  
3 Proceed to isopropanol precipitation or store reactions in the –200C 
freezer overnight. 
 
                                  
 
B. To Purify with Ethanol/Sodium Acetate precipitation Method. 
 
 Prepare the sodium acetate/ethanol solution by combining the following per 
reaction 
2 uL of 3.0 M sodium acetate, pH 5.2 
50 uL of 100% ethanol 
70% ethanol  
  
 
Note: Perform the inverted spin immediately after centrifugation to avoid loss of DNA. 
If the plate sits longer than 1 minute before the inverted spin is performed, spin it for 
an additional 5 minutes to improve recovery. 
 
C. Storing the purified sequencing reactions: 
Step Action 
1 Add 52 uL of sodium acetate/ethanol solution to each sequencing reaction 
2 Seal the tubes with strip caps or the plate with adhesive aluminum foil tape 
3 Mix by vortexing. 
IMPORTANT! Mix thoroughly at this step. This is essential for efficient 
precipitation. 
4 Centrifuge at 20,000 X g for 20 minutes. 
5 As soon as the centrifuge stops, remove the caps or tape without disturbing the 
pellets. 
6  Immediately place an absorbent paper towel or lint-free tissue on top of the plate 
and invert it. 
7 Centrifuge 150 X g for 1 minute  to remove supernatant solution 
8 Add 150 uL of 70% ethanol to each well  
9 Centrifuge at 2,000 X g for 5 minutes. 
10 Immediately place an absorbent paper towel or lint-free tissue on top of the plate 
and invert it. 
 
11 Centrifuge 150 X g 1 minute to remove supernatant solution 
12 When the centrifuge stops and drying is complete, remove the tray/plate and seal 
with strip caps or aluminum tape, then store at -15 to -25oC in the dark. 
Analyze the samples within one week. 
IMPORTANT! Use a dark box for storage. The products of sequencing reactions 
are light sensitive. 
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If you plan to..... Then..... 
Load the purified sequencing 
reactions on the 3130xl within 2 
hours 
Place the reactions in the refrigerator until you are 
ready to prepare them for analysis on the 3130xl 
Avoid exposing the samples to light. 
Continue another time (samples 
may be stored for up to six 
months) 
Wrap the plate with the samples with aluminum 
foil to protect them from light and store them in 
the -20 freezer. 
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